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ABSTRACT 
Cancer is a major public health challenge and the second leading cause of death 
in the United States. Large amount of effort has been made to achieve sensitive and 
specific detection of cancer, and to predict the course of cancer. Glycans are promising 
avenues toward the diagnosis and prognosis of cancer, because aberrant glycosylation 
is a prevalent hallmark of diverse types of cancer. A bottom-up “glycan node analysis” 
approach was employed as a useful tool, which captures most essential glycan features 
from blood plasma or serum (P/S) specimens and quantifies them as single analytical 
signals, to a lung cancer set from the Women Epidemiology Lung Cancer (WELCA) 
study. In addition, developments were performed to simplify a relatively cumbersome 
step involved in sample preparation of glycan node analysis. Furthermore, as a 
biomarker discovery research, one crucial concern of the glycan node analysis is to 
ensure that the specimen integrity has not been compromised for the employed P/S 
samples. A simple P/S integrity quality assurance assay was applied to the same sample 
set from WELCA study, which also afford the opportunity to evaluate the effects of 
different collection sites on sample integrity in a multisite clinical trial.   
Here, 208 samples from lung cancer patients and 207 age-matched controls 
enrolled in the WELCA study were analyzed by glycan node analysis. Glycan features, 
quantified as single analytical signals, including 2-linked mannose, α2‐6 sialylation, 
β1‐4 branching, β1‐6 branching, 4-linked GlcNAc, and outer-arm fucosylation, 
exhibited abilities to distinguish lung cancer cases from controls and predict survival in 
patients. 
To circumvent the laborious preparation steps for permethylation of glycan 
node analysis, a spin column-free (SCF) glycan permethylation procedure was 
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developed, applicable to both intact glycan analysis or glycan node analysis, with 
improved or comparable permethylation efficiency relative to some widely-used spin 
column-based procedures.  
Biospecimen integrity of the same set of plasma samples from WELCA study 
was evaluated by a simple intact protein assay (ΔS-Cysteinylated-Albumin), which 
quantifies cumulative exposure of P/S to thawed conditions (-30 °C). Notable 
differences were observed between different groups of samples with various initial 
handling/storage conditions, as well as among the different collection sites. 
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CHAPTER 1 
INTRODUCTION 
1.1 Glycans and Lung Cancer Diagnosis 
Glycans are complex biological sugar polymers that are usually attached to 
proteins and lipids and are often displayed on cell surfaces. Like nucleic acids, proteins 
and lipids, glycans are primary constituents of cells and play significant roles in many 
vital biological processes. The biological functions of glycans span a wide range: 1) 
structural and modulatory functions, such as facilitating protein folding; 2) specific 
recognition by intrinsic and extrinsic glycan-binding proteins, such as those involved 
in signal transduction; 3) cellular adhesion; and 4) molecular mimicry of host glycans. 
But among the four major classes of biomolecules, the analysis of glycans is the most 
challenging, mainly due to the abundance and enormous structural diversity of glycans 
as well as the fact that they are not constructed in a template-driven manner. 
Nevertheless, in the past few decades, impressive progress has been achieved in the 
development of technologies, especially in mass spectrometry, that benefit glycan 
analysis1. The advances in ionization technologies2, 3, evolved methods of ion 
activation4, 5, improved chromatographic separations6-8, and introduction of ion 
mobility mass spectrometry9 all expedite the characterization of glycans. Glycomics is 
the comprehensive study of glycans, in the forms of oligosaccharide polymers, N- and 
O-linked glycoproteins, glycolipids, and proteoglycans. Glycosylation describes the 
process of attaching glycans to proteins or other biological molecules in endoplasmic 
reticulum (ER) and golgi apparatus organelles. And the altered glycosylation has long 
been discovered as a universal feature of cancer cells10.  
1.1.1 Alteration of Glycan Features in Cancer 
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1.1.1.1 Heterogeneity and Consistency of Glycan Construction 
Glycosylation is the most common and well-known post-translational 
modification (PTM) reaction. It is catalyzed by enzymes called glycosyltransferases 
(GTs). Glycosyltransferases assemble monosaccharide moieties to form linear or 
branched glycan chains, by transferring and attaching the monosaccharide moiety of a 
donor substrate to the acceptor substrate, using an SN2 (substitution nucleophilic 
bimolecular) reaction mechanism11. The most common glycosyl donors in eukaryotic 
cells are nucleotide sugars, such as Uridine diphosphate (UDP)-glucose and 
Guanosine diphosphate (GDP)-mannose. And acceptors are commonly 
oligosaccharides, proteins, lipids and sometimes DNA.  
Unlike the synthesis of DNA, RNA and proteins, there is no biologically 
embedded template for glycan construction. Despite the fact that most human glycans 
are comprised of only nine major monosaccharides, the large family of GTs together 
with their non-template-driven manner lead to the natural complexity and structural 
heterogeneity of glycans. However, among the seemingly chaotic process, the strict 
acceptor, donor, and linkage specificity11 of GTs contribute to moderate degree of 
consistency of glycan construction. In general, each glycosyltransferase catalyzes the 
formation of a single glycosidic linkage12, 13. An excellent example of the specificity 
can be provided by human B blood group α1–3 galactosyltransferase, as illustrated in 
Fig. 1.1. The B transferase adds galactose (from its specific donor UDP-galactose) in 
unique α1–3 linkage to H antigen, the specific acceptor of this enzyme. The strict 
acceptor substrate specificity of B transferase lies in the fact that it only acts on the 
α1–2-linked fucose modified H antigen, but not on the unmodified type-2 precursor or 
other modified form of the precursor. Exceptions to the strict donor, acceptor, and 
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linkage specificity exist in instances that more than one GT share the same acceptor 
and make the same linkage, such as human fucosyltransferases III–VII14. Other 
examples include GTs that catalyzes multiple reactions (β1-4 galactosyltransferase15-
17) and those with two separate active sites (such as those that synthesize the 
backbones of glycosaminoglycans). Nevertheless, most GTs exhibit the specificity 
strictly and thus define and limit the number and type glycan structures present in a 
given organism11.  
1.1.1.2 N-glycans, O-glycans and Glycolipids 
The three major forms of glycans prevalent in most eukaryotes are N-glycans, 
O-glycans and glycolipids. (Abbreviations of commonly seen monosaccharide moieties 
are provided above.) 
N-glycans are covalently linked to the nitrogen in the side chain of asparagine 
(Asn) by an N-glycosidic bond. A sequon beginning with asparagine followed by any 
amino acid except proline and ending with serine or threonine (Asn-X-Ser/Thr) is a 
requisite for a protein to receive N-glycans. A common core structure, Man α1-
6(Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAcβ1-Asn-X-Ser/Thr, is shared by all N-
glycans. N-glycans are classified into three types based on the composition of their 
“antennae” attached to the core sequence (Fig. 1.2): 1) oligomannose, with the 
antennae composed of only mannose residues; 2) complex, consisting of antennae that 
add a GlcNAc residue (usually followed by Galactose and Sialic acid attachment) to 
the Manα1-3 and Manα1-6 arms; 3) hybrid, with mannose residues linked to the 
Manα1-6 arm and one or two antennae initiated with GlcNAc residue linked to the 
Manα1-3 arm.  
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Our understandings of the N-glycans biological functions have been 
enormously advanced in the past few decades. The research reported by Ari Helenius 
and colleagues elucidated the crucial function of the N-glycans in facilitating the 
proper folding of proteins18, 19. In brief, calnexin and calreticulin in ER, which serve 
as chaperones for the newly synthesized glycoproteins during their folding so that 
they do not aggregate, or leave the ER prematurely, bind specifically to the three 
glucose residues of the N-glycans attached to a nascent polypeptide20, 21. The three 
glucose residues will be trimmed if the glycoprotein has properly folded, otherwise 
reattachment of the three glucose residues onto the N-glycan structure and further 
folding processes will subsequently occur. Additionally, N-glycans play key roles in 
signaling. As revealed by Wang et al., deficiency of the core fucosylation down-
regulated several receptor-mediated signaling pathways, including transforming 
growth factor (TGF)- β1 receptor, epidermal growth factor (EGF) receptor, and 
integrins, which are responsible for cell growth, differentiation, and emphysema22. 
Moreover, N-glycans present in the fragment crystallizable (Fc) region of 
immunoglobulin (Ig) facilitate the dictation of the antibody’s effector function23. 
O-glycans are covalently linked to hydroxyl group (-OH) of serine (Ser) or 
threonine (Thr) by an O-glycosidic bond. Unlike N-glycans, no consensus sequence 
of the receiving peptide chain for O-glycans is discovered yet. There are several types 
of O-glycans, among which the α-linked O-GalNAc glycans from mucin are the most 
ubiquitous and crucial. Four common core structures, which can be subsequently 
extended to form mature linear or branched O-GalNAc glycans, are illustrated in Fig. 
1.3.  
Many essential biological functions of O-glycans have been discovered. The 
mucin O-GalNAc glycans are essential in promoting mutualism with the commensal 
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microbiota in the intestinal tract24. The core 1-derived O-GalNAc glycans25 are 
pivotal in sustaining the protective homeostatic mucus barrier between the resident 
microbiota and the underlying immune cells in the colon. Meanwhile, lack of the core 
3-derived O-GalNAc26 can lead to physiological defects, including increases in 
intestinal permeability and higher levels of colonic bacteria within the colonic 
mucosa. Another important O-glycan, Sialyl-Lewisx (SLex) plays vital role in cell-cell 
interaction27 and serves as an essential blood group antigen. Furthermore, SLex is 
critical to immune and inflammatory response28.     
Glycolipids are lipids covalently attached by glycans with a glycosidic bond. 
Glycosphingolipids (GSLs) and glycoglycerolipids are the two major types of 
glycolipids, that are glycans built on a ceramide lipid moiety that consists of a long-
chain amino alcohol (sphingosine) in amide linkage to a fatty acid, and a diacyl or 
acylalkylglycerol lipid moiety, respectively29. Besides the β-linked 
galactosylceramide (GalCer) and its analog sulfatide that are prevalent especially in 
brain, most complex vertebrate glycosphingolipids share a fundamental core structure 
lactosylceramide (Galβ1-4GlcβCer). Structures of representative glycolipids for the 
two types and one example of a complex sialylated GSL are provided in Fig. 1.4. 
Complex glycosphingolipids function both in cell-cell recognition and in the 
regulation of signal transduction30, as their trans recognition roles. When it comes to 
the cis recognition role, they also interact laterally with proteins in the same membrane 
to modulate their activities31. The simple glycolipid GalCer functions as obligate 
precursor to the ceramide required to build the outermost protective layer (stratum 
corneum) of the skin32. And its analog sulfatide have essential roles in myelin-axon 
interactions, the absence of which leads to serious neurological deficits33. 
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1.1.1.3 Changes of Glycans in Cancer and the Associated Functions 
Altered glycosylation is a universal hallmark of various cancer types. There are 
a few different forms of glycan alteration in malignant cells: increased expression of 
and decreased expression of certain glycans, overexpression of truncated and 
incomplete glycans, and emergence novel glycans10. The changes of several common 
glycan forms are listed and discussed below.  
Many studies have revealed the changes of N-glycans in a variety of cancer 
types, as well as their significant functions in facilitating the metastasis and progression 
of cancer. Increased β1-6 branching N-glycans, resulted from excessive expression of 
N-acetylglucosaminyltransferase V (GlcNAc-TV, or MGAT5) and the upstream 
enhanced transcription of the MGAT5 gene, were suggested to expedite the metastasis 
process of tumor cells10, 34-36. As reported by Seberger et al.36 in 1999, the transfected 
mouse mammary cancer cell lines with increased β1-6 branching on the cell surface 
formed elevated levels of lung tumors with 4- to 40-fold in metastatic potential in mice 
relative to control transfected cell lines. Another persuasive evidence comes from the 
research performed by Granovsky et al35. that revealed suppression of tumor growth 
and metastasis in MGAT5-deficient mice. Besides, increased β1-4 branching tetra-
antennary N-glycans, arisen from the overexpression of MGAT4 gene, also contribute 
to tumor progression10, 37. The increased N-glycan branching, together with enhanced 
out-arm fucosylation38, give rise to tumor metastasis and progression, probably by the 
generation of poly-Nacetyllactosamines (LacNAc) and SLex (ligands for galectin and 
selectin, respectively) and subsequently extended growth-factor signaling10, 37.  
The altered O-glycans in cancer also exhibit crucial functions. Mucins, which 
carry plenty of O-GalNAc glycans, were disclosed to promote the metastasis of tumor 
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cells and inhibit the activity of cytolytic cells such as natural killer cells39. Due to the 
rod-like structure and negative charge, mucins are capable to repel intercellular 
interactions, for instance between blood-borne tumor cells and host cytolytic cells40, 
41. Also, the structural property enables mucins to sterically inhibit the activities of 
other adhesion molecules as cadherins and integrins, and lead to the initiation of 
tumor metastasis42, 43.  Moreover, the antigen peptides present on the surface of major 
histocompatibility complex (MHC) may be blocked by mucins10. The carcinoma 
mucins feature by their incomplete glycan forms, primarily Tn (GalNAcα1-O-
Ser/Thr), T (Galβ1-3Tn) and sialyl Tn (NeuNAcα1-6Tn, sTn) antigens44, that are 
correlated with silencing of the COSMC gene (C1GALT1C1) and overexpression of 
the sialyltransferase ST6GALNAC1. 
Some glycolipids are largely overexpressed in specific cancers. For instance, 
GD2 and GD3, disialogangliosides highly enriched in on tumors of neuroectodermal 
origin, are involved in the attachment of human melanoma and neuroblastoma cells to 
extracellular matrix proteins, as suggested by Cheresh et al45. Yet the modulatory 
mechanism of gangliosides remains obscure. Fishman and colleagues46 had reported 
gangliosides as a bimodal regulator of cell growth, which may either promote or 
inhibit cell growth depending on the state of growth of the target cell. 
Altered expression of sialic acid is another representative and early-observed 
hallmark of cancers. Increased α2-6 sialylation on the outer LacNAc units, resulted 
from the upregulation of ST6GAL1gene, was indicated to promote tumor 
progression10, 47, by enhancing integrin48, 49 activity and cell motility49, 50, and 
suppressing galectin-3-induced apoptosis51 and Fas death receptor activity52. 
However, the modulatory role of α2-6 sialylation in cancer is controversial, with some 
8 
studies discovered that it also inhibits tumor progression53 by hindering the binding 
between epidermal growth factor (EGF) and EGF receptor. 
Heparan sulfate (HS) is a unique sulfated glycosaminoglycan (GAG) that has 
been implicated in tumor pathogenesis10, 54, primarily by promoting invasion55, 56, 
metastasis56 and angiogenesis57. HS covalently linked proteoglycans are found to 
facilitate cell-cell and cell-matrix interactions58 and bind numerous growth factors, 
such as fibroblast growth factor-2 (FGF-2)59 and vascular endothelial growth factor 
(VEGF)60, and a variety of other chemokines61 and cytokines62. 
1.1.2 Glycan Markers in the Detection of Lung Cancer 
Up to now, the greatest number of cancer death in United States comes from 
lung cancer, with an estimate of 142,670 deaths in 201963. Lung cancer is categorized 
into two main histological types, small cell lung carcinomas (SCLC) and non-small cell 
carcinomas (NSCLC). The second histology type covers more than 80% of lung cancer 
and consists of three subgroups: adenocarcinoma, squamous cell carcinoma and large 
cell carcinoma. Currently, the detection and diagnosis of lung cancer largely rely on 
chest X-ray films and computed tomography (CT) scans. The lack of early stage 
symptoms and diagnostic technologies with acceptable sensitivity and specificity give 
rise to less than 5% five-year survival rate of lung cancer63. Lung cancer is known to 
closely associated with various glycosylation changes64, which can potentially serve as 
glycan-based markers to aid in lung cancer diagnosis, especially in early stage.  
It has been reported by Zhang et al. in 1997 that lung cancer cells upregulated 
the expression of sialylated and fucosylated glycan epitopes on the cell surface65, 66, 
including SLex, SLea, sTn, Ley, gangliosides GM2, fucosyl GM1, Globo H, polysialic 
acid, etc. Further studies focusing on uncovering the link between glycosylation and 
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protein functions were carried out by Liu et al.67 using the more recent technologies-
alkyne-sugar probe and Cu [I]-catalyzed alkyne-azide click chemistry68. By comparing 
the sialylation and fucosylation levels of two lung cancer cell lines derived from same 
parental cell line but with distinct invasiveness (CL1-5, high invasive and CL1-10, low 
invasive), Liu and colleagues identified greatly higher expression level (22.5 folds) of 
FUT8 gene in the move invasive lung cancer cell line (CL1-5). The overexpressed α1,6-
fucosylatransferase (FUT8) and corresponding core fucosylation glycan feature was 
found to be essential to EGFR dimerization and phosphorylation, and the consequential 
binding affinity to EGF67.  
Lung cancer and smoking-induced changes in N-glycosylation of blood serum 
proteins were evaluated by Vasseur et al, with the discovery of elevated level of 
fucosylated tetra-antennary structures with varying degrees of sialylation in lung cancer 
patients. Further investigation revealed that outer-arm fucosylation, particularly for the 
tri- and tetra-antennary structures, was elevated in both lung cancer patients and 
controls with previous smoking history. Besides, increased α2,6-linked sialic acids 
isoform and decreased α2,3-linked sialic acid isoform were also observed in former 
smokers69. Recently, Arnold et al. reported several novel glycan biomarkers for lung 
cancer detection, including increases of SLex, monoantennary glycans, highly sialylated 
glycans and decreases of core-fucosylated biantennary glycans, with some being 
detectable as early as in Stage I70. In 2018, Ferdosi et al.71, 72 evaluated the detection 
and prediction performance of plasma and serum glycomics in lung, prostate, serous 
ovarian, pancreatic and bladder cancer, indicating stage dependent, cell-origin 
independent diagnostic and prognostic capacity of serum glycan fucosylation, α2‐6 
sialylation, β1‐4 branching, β1‐6 branching in lung and bladder cancer. 
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1.2 Permethylation of Glycans 
The unprecedented progress in the development of matrix-assisted laser 
desorption/ionization (MALDI) and electrospray ionization (ESI) MS has substantially 
expedited structural analysis of glycans in the last two decades. Although most glycans 
can be directly analyzed by MALDI-MS in their native form, several pronounced 
advantages can be conferred to the structural analysis of glycans by permethylation73: 
1) the methyl groups added to all the hydroxyl and N-acetyl groups within 
oligosaccharide polymer during permethylation increase the hydrophobicity of glycan, 
which facilitates the separation by LC-MS; 2) sialic acid, as the most labile 
monosaccharide moiety, can be stabilized by methylation, with the carboxyl functional 
group methyl esterified; 3) the ionization efficiency and quantitative reproducibility of 
glycans on MS (especially MALDI- and ESI-MS) can be considerably enhanced; 4) 
determination of branching and glycosidic linkage positions can be easily achieved74, 
75; 5) more predictable spectral patterns can be generated for tandem mass spectral 
analysis (MS/MS)76. 
1.2.1 Historical Development of Permethylation 
The development history of permethylation procedure spanned over a century77. 
The first glycan methylation procedure was developed by Prudie and Irvine in 190378, 
in which carbohydrates were dissolved in methanol, reacted with methyl iodide (MeI) 
in the presence of silver oxide. About a decade later, Haworth et al.79 introduced methyl 
sulfate as the methylation reagent and sodium hydroxide solution to react with 
carbohydrates dissolved in trace amount of water. To improve the undesirable 
methylation yields from these two procedures, in 1960s80-83, the methylsulfinyl 
carbanion (dimsyl) and dimethyl sulfoxide (DMSO) were introduced as catalyst and 
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solvent respectively, with methyl iodide working as methylation reagent. Nevertheless, 
even with obviously enhanced methylation yield and achievement of permethylation of 
carbohydrates in one step, the preparation of dimsyl reagent, which is extremely 
sensitive to air, moisture and carbon dioxide, remained laborious and hazardous. In 
1984, Ciucanu and Kerek utilized powdered sodium hydride (NaH) to substitute Na 
dimsyl, with methyl iodide and DMSO remained in the procedure84. Yet, this procedure 
that was widely adopted by many glycan studying laboratories required quite large 
quantity of carbohydrates. Subsequently, in 2005, Mechref, Novotny and colleagues85 
developed a solid-phase spin column-based procedure, where carbohydrates dissolved 
in DMSO were proposed to react with methyl iodide on the surface of NaOH beads. 
This procedure was adopted and optimized by Borges group74, 75, and employed to 
various types of cancer sets. 
1.2.2 Reaction Mechanism of Permethylation 
The mechanism of NaOH beads-based permethylation procedure optimized by 
Borges group is described below. The solvent used to dissolve glycan sample solution 
as well as plasma or serum samples is DMSO with trace amount of water. The NaOH 
beads are responsible for generating alkaline condition. As depicted in Fig. 1.5, the 
permethylation reaction is carried out in an SN2 mechanism. Firstly, all free hydroxyl 
groups within the polysaccharide structure are deprotonated by NaOH, to generate 
alkoxide ions (RO-). Next, the alkoxide ions work as powerful nucleophiles and attack 
the electrophilic carbon in methyl iodide, with the leaving group iodine ion leaving and 
the methyl group covalently linked to the alkoxyl group. The yield of this 
permethylation step with 24% w/w of NaOH/DMSO condition is about 99%.86, 87 Thus, 
even though the undermethylated byproducts of permethylation step may interfere with 
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the subsequent analysis and lead to biased result, the undermethylation of 
polysaccharides can often be minimized, with negligible effects on the quantitative 
determination of glycosidic linkage positions. 
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1.3 Plasma/Serum Integrity and Ex Vivo Oxidation of Albumin 
In the past few decades, the remarkable progresses in the development of 
automation instrument and computer sciences, accompanied by the implementation of 
high-quality analytical standards, have substantially improved the quality of lab 
testing results and diminished analytical errors. Hence, more attentions have been 
focused on errors incurred in the pre-analytical phase, primarily due to the fact that it 
is currently difficult to monitor all the preanalytical variables (PAVs), especially 
when they are not under direct laboratory supervision88, 89. Compromised integrity of 
biospecimens should pertain to the loss of an ability to accurately quantify one or 
more analytes—i.e, a sample’s “integrity” depends on what analytes are going to be 
analyzed and whether or not they’ve remained stable. PAVs that largely impact the 
integrity of biospecimens pervade in the following four steps: collection, processing, 
transport and storage. Notably, the research presented in this dissertation is primarily 
concerned with handling and storage conditions that result in the exposure of 
specimens to thawed conditions—e.g., for blood plasma and serum, temperatures > -
30 °C90, 91—because this is often the most difficult PAV to control and track over the 
lifetime of a specimen collected and archived for research purposes. 
1.3.1 Plasma/Serum Handling and Integrity 
Among a variety of biospecimens that are commonly used in clinical chemistry 
laboratories, plasma/serum (P/S) samples stand out with the prominent advantage that 
most analytes of interest are available in blood biospecimen. Even with some 
disadvantages due to mildly painful collection, blood samples account for more than 
half of the biospecimens included in the National Cancer Institute (NCI)-sponsored 
projects92.  
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PAVs involved in the collection step of P/S samples are brands of collection 
tube, additives added in collection tube (EDTA, heparin, sodium fluoride/potassium 
oxalate), types of specimens (whole blood, plasma, or serum), mixing of blood, 
hemolysis, and so on. In 2001, Evans et al.93 tested the effect of several prevalent 
additives used in blood collection on stability of plasma and serum hormones. They 
recommended the utilization of EDTA as the anticoagulant added in blood collection 
tube when hormones are the analytes of interest, because both heparin and fluoride 
significantly affected concentrations of some hormones relative to EDTA. 
Within the processing step of P/S samples, considerable alterations of sample 
integrity could come from many important PAVs, such as speed, gravity, temperature 
and duration of centrifugation. Reisch et al.94 suggested that preanalytical stability of 
adrenocorticotropic hormone (ACTH) relied more on time to centrifugation than 
temperature, with significantly decreased ACTH concentrations in uncentrifuged 
samples compared to centrifuged samples stored at same temperature (4 ℃). According 
to Tanner and colleagues95, delay in centrifugation at various temperatures up to 24 
hours significantly affected some analytes such as potassium, urea, glucose, iron, and 
ferritin. And generally, temperature-controlled centrifuges are recommended96. 
Essential PAVs for transport and long-term storage of P/S samples include 
exposure to thawed conditions (> -30 ℃ 90, 91) probably due to loss of dry ice, storage 
duration and temperature, and numbers of freeze-thaw cycles (FTCs). Holland et al.97 
have reported that repeated freeze-thaw cycles can be detrimental for some analytes in 
blood samples, such as RNA. Therefore, aliquots should be created upfront rather than 
delayed, to avoid repeated FTCs. The storage temperature also matters for blood sample 
integrity. A variety of plasma/serum (P/S) analytes were found to be unstable when 
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stored in -20 ℃ for longer than 3 months, such as VEGF-receptor98, thromboplastin 
and prothrombin99, etc. Even stored at -80 ℃, some analytes were revealed to be 
unstable after a certain storage duration. For example, matrix metalloproteinases 
(MMP)-9100 was found to loss stability within one-month storage in -80 ℃, while 
apolipoprotein E101 was reported to be stable for only 3 months in -80 ℃. 
To circumvent the issue of fluctuated P/S sample integrity due to so many PAVs, 
substantial efforts have been made to accelerate the development of standard operating 
procedures (SOPs), that guide the collection, processing, transport and storage 
conditions for blood specimens. Nevertheless, a rigid SOP—while appealing to 
administrators—may be difficult and impractical to follow for some collection sites, 
because of possible logistical and financial restrictions. Furthermore, some PAVs and 
conditions are not easy to keep track of and document in detail, such as delay in 
shipments and failure of a freezer. Hence, an accurate endogenous marker to assure the 
integrity of P/S samples, especially for those that are pre-existing or lack detailed paper 
trials, is essential and beneficial. Recently, the Borges group102 has developed a "ΔS‐
cysteinylated‐albumin" (ΔS‐Cys‐Alb) assay, which measures the ex-vivo oxidizability 
of human serum albumin (HSA) and applies it as a QC/QA marker of P/S integrity. 
 
1.3.2 Harnessing Albumin as a Marker of P/S Integrity 
1.3.2.1 Structure and Biological Functions of Human Serum Albumin 
Human serum albumin (HSA) is the most abundant circulating protein in human 
P/S, which accounts for over 50% of total plasma proteins. The composition and 
structure of HSA has been well understood by scientists103, 104. The native HSA is a 
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non-glycosylated protein composed by 585 amino acids and 3 domains, with a 
molecular weight of 66438 Dalton (Da). There are a total 35 cysteine residues in HSA 
sequence, forming 17 disulfide bonds and nine (practically eight and half) double loops. 
The double loops are further grouped into three homologous domains, each of which 
consisting of 2 longer loops with a shorter loop in between.  In each domain, the first 
two loops are grouped as subdomains A (IA: loop 1-2; IIA: loop 4-5; IIIA: loop 7-8) 
and the third loop is referred as subdomain B (IB: loop 3; IIB: loop 6; IIIB: loop 9). 
The hydrophobic cavities in subdomains IIA and IIIA are the primary ligand binding 
regions of HSA. The cysteine residue at position 34 (Cys34) of HSA is primarily free 
and can react with other circulating molecules. 
HSA has many essential biological functions, such as maintaining osmotic 
pressure, binding to endogenous and exogenous compounds, balancing the redox state, 
providing inflammatory and/or immunological responses, and regulating the 
pharmacokinetic and pharmacodynamics of many drugs104, 105. As the predominate 
plasma protein with such a large molecular weight, HSA acts as the main modulator of 
plasma oncotic pressure106. The negative net charge of HSA at physiological pH also 
contribute to its oncotic capacity by Gibbs-Donnan effect-i.e., by attracting positively 
charged counter-ions to the intravascular compartment104. In addition, the binding sites 
located in subdomains IIA and IIIA enable the binding of HSA to fatty acids, hormones, 
ions and drugs, which consequently increases the solubility of the bound compounds 
and favors their distributions to the action sites107. Furthermore, the antioxidant activity 
of HSA comes from the free cysteine residue Cys34 that is capable to bind to reactive 
oxygen species (ROS)108, 109, and the six methionine residues which can be oxidized to 
sulfoxides110-112. The N-terminus of HSA is also adjuvant to its antioxidant capacity, by 
17 
chelating redox-active transition metal ions and preventing them from catalyzing the 
formation of hydroxyl radicals111, 113. Moreover, HSA binds to surface components of 
gram-negative and gram-positive bacteria that activate the innate immune system 
through Toll-like receptor 4 (TLR4) and induce inflammation114-116. Besides, binding 
to HSA controls the free, active concentrations of many drugs and may affect 
considerably their overall pharmacodynamic and pharmacokinetic profile117-119. 
1.3.2.2 Ex Vivo Oxidizability of Albumin as a Marker of P/S Integrity 
Some evidence exists that albumin is susceptible to ex vivo oxidation120. 
Recently, Borges group has performed systematic studies of the ex vivo oxidation of 
albumin102, 121, 122. It has been well known that free thiol-containing molecules, such as 
albumin, will spontaneously form intra- or intermolecular disulfide bonds in air-
exposed aqueous solutions, in the absence of special precautions. As shown by 
numerous groups over the past few decades123-125, this spontaneous process only 
requires atmospheric oxygen and trace metals and, as shown by the Borges group, 
occurs, in part, through a cysteine sulfenic acid (Cys-SOH) intermediate121. The S-
cysteinylation of albumin through disulfide exchange with cystine (the dimerized form 
of cysteine) present in P/S, also occurs and appears to be the dominant mechanism 
governing the ex vivo oxidative S-cysteinylation of albumin. The reactions governing 
the ex vivo formation of S-cysteinylated albumin (S-Cys-Alb) are as follows:  
 
Where AlbSH represents the native reduced form of albumin, Cys-Cys 
represents cystine, SCysAlb stands for S-cysteinylated albumin, and Cys stands for 
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cysteine102. 
All the reactants listed in the equations above are naturally present in P/S 
samples. The average initial starting concentrations of albumin, cysteine, cystine, and 
copper in P/S are all known from previously published literature or simply measured 
by Jeffs et al., that are 650 ± 60 µM126, 11 ± 1 µM, 70 ± 10 µM127, 128 and  18.7 ± 9.2 
µM102, respectively. As determined by Jeffs et al.102, the starting concentration of S-
cysteinylated albumin is usually 20 – 30%. Also, oxygen only enters P/S ex vivo, 
because oxygen carried by hemoglobin in red blood cells is not exposed to P/S in vivo. 
And the hydrogen peroxide (H2O2) present in P/S is almost immediately decomposed 
by catalase present in P/S, with no interference with the S-cysteinylation of albumin. 
Besides, the rate law for reaction 2 (k3 = 0.13 M‐1 s‐1) can be estimated from the value 
for 37 ℃ reported by Kachur et al.124 And finally, the rate laws for the forward and 
reverse reactions in reaction 1 at 23 ℃ have been determined by Jeffs et al.102, with k1 
and k2 reported to be 0.095 ± 0.017 M‐1 s‐1 and 3.37 ± 0.44 M‐1 s‐1, respectively. 
As mentioned previously, the Borges group has developed a simple dilute-and-
shoot procedure for the ΔS‐Cys‐Alb assay102. This assay meets most of the ideal 
QA/QC marker requirements, including: targeting an endogenous analyte (albumin in 
P/S), requiring very low sample volume (10 µL), minimal sample preparation (less than 
5 minutes preparation time), inexpensive and rapid, simultaneous change with the most 
fragile time-sensitive analytes in P/S, and unaffected by any stabilization practices such 
as protease inhibitors. Moreover, the theoretical reference range for ΔS‐Cys‐Alb in > 
99% of the population has already been estimated as 11-39% from the known 
population reference ranges for albumin126, cysteine, and cystine127, 128—assuming 
albumin is the only oxidative consumer of Cys equivalents. Recent findings by Jeffs et 
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al.102 in fresh P/S collected from non-acute cardiovascular patients have empirically 
confirmed this range. (Further validation in fully healthy donors is presently underway.) 
With the rate laws established for the ex vivo formation of S-Cys-Alb and verified to 
accurately model these reactions in actual P/S102, it is possible for the ΔS‐Cys‐Alb assay 
to effectively place an exposure time stamp on every sample. The application of this 
ΔS‐Cys‐Alb assay onto a large set of clinical plasma samples collected under a single 
SOP but from different collection sites in a multisite clinical trial is described in detail 
in Chapter 4.  
  
20 
Figures 
 
Figure 1.1. The strict acceptor substrate specificity of glycosyltransferases is illustrated 
by the human B blood group α1-3 galactosyltransferase. The B transferase adds 
galactose in α1-3-linkage to the H antigen (top). This enzyme requires the α1-2-linked 
fucose modification of the H antigen for activity because the B transferase does not add 
to an unmodified type-2 precursor (middle), or precursors modified by sialyl residues 
(bottom) or other monosaccharides (not shown). The monosaccharide symbol codes are 
shown in the legend on the right. Adapted with permission from Rini et al.11. 
  
21 
 
Figure 1.2. Types of N-glycans. N-Glycans at Asn-X-Ser/Thr sequons in eukaryote 
glycoproteins are of three general types: oligomannose, complex, and hybrid. Each N-
glycan contains the common core Man3GlcNAc2Asn. Adapted with permission from 
Stanley et al.129. 
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Figure 1.3. Complex O-GalNAc glycans with different cores (identified by gray boxes). 
Extended core 1, 2, 3, or 4 O-GalNAc glycans are from human respiratory mucins and 
the extended core 3 O-GalNAc glycan is from human colonic mucins. All four core 
structures (in boxes) may be extended, branched, and terminated with Fuc, Sia, or blood 
group antigenic determinants. Core 1 and 3 O-GalNAc glycans may also carry α2-6 Sia 
linked to the core GalNAc. Green lines are protein. Adapted with permission from 
Brockhausen et al.130. 
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Figure 1.4. Structures of representative glycosphingolipids (GSLs) (left) and 
glycoglycerolipids (middle), and a complex sialylated GSL (right). GSLs, such as 
GalCer, are built on a ceramide lipid moiety that consists of a long-chain amino alcohol 
(sphingosine) in amide linkage to a fatty acid. In comparison, glycoglycerolipids, such 
as seminolipid, are built on a diacyl or acylalkylglycerol lipid moiety. Most animal 
glycolipids are GSLs, which have a large and diverse family of glycans attached to 
ceramide. Shown in right is one example of a complex sialylated GSL, GT1b 
(IV3Neu5AcII3[Neu5Ac]2Gg4Cer). Adapted with permission from Schnaar et al.29. 
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Figure 1.5. Substitution nucleophilic bimolecular (SN2) mechanism of permethylation 
step.  
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CHAPTER 2 
DIAGNOSTIC AND PROGNOSTIC PERFORMANCE OF BLOOD PLASMA 
GLYCAN FEATURES IN THE WOMEN EPIDEMIOLOGY LUNG CANCER 
(WELCA) STUDY 
2.1 Introduction 
Lung cancer is the leading cause of cancer death in the United States, which 
accounts for approximately 25% of cancer deaths63. About 33 % and 40% of lung 
cancer patients are diagnosed at stage IIIB and IV respectively131, primarily due to a 
lack of early stage symptoms. The five-year survival rate of stage IV patients is only ~ 
5%63. Conversely, if lung cancer can be detected before it escapes the lungs, the five-
year survival rates usually exceed 50%63. Therefore, to improve the outcome of lung 
cancer patients, a major clinical priority is to detect lung cancer early. Recently, the 
National Lung Screening Trial (NLST) applied low dose chest computed tomography 
(LDCT) in older, high-risk individuals and achieved 20% reduction in lung cancer 
mortality. Yet the positive screening rate in this study was 24.2%, of which 96.4% were 
false-positive results132. The high false-positive rate may lead to additional clinical tests 
and unnecessary treatments, as well as unnecessary time and costs spent. Thus, a 
reliable, and highly specific non-invasive blood test could help to reduce the false-
positive and overdiagnosis rate of CT scans.  
Biomarkers from easily accessible biofluids, such as blood plasma and serum 
(P/S), could be used as a non-invasive and cost-effective way to improve lung cancer 
diagnosis and screening. Numerous P/S biomarkers for lung cancer have been 
extensively studied, including proteins (such as cytokeratin 19 fragments133, 134 and 
carcinoembryonic antigen135, 136), miRNAs (such as miR-34137 and miR-182138, 139), 
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methyl-DNA (such as P16140 and BRMS1141), and circulating tumor cells142. However, 
biomarkers with more improved sensitivity and specificity are still in needed. 
Aberrant glycosylation is a well-established hallmark of cancer and seems to 
facilitate the metastasis of various tumor cells10. Thus, blood plasma and serum 
glycomics represents a promising source for a new generation of cancer biomarkers. At 
present, almost all P/S glycomics studies focus on the analysis of intact glycans, 
primarily N-linked glycans with O-linked and lipid-linked glycans usually excluded. 
Generally, a great many intact glycan structures need to be investigated in order to fully 
capture and quantify the cancer-specific behavior of one unique glycan feature, such as 
core fucosylation, α2-6 sialylation or β1-4 branching143. Glycan node analysis, is a 
molecularly bottom-up approach to P/S glycomics developed by Borges et al. in 2013, 
that focuses on monosaccharides and linkage specific “glycan nodes” rather than the 
intact glycan structures71, 72, 74, 75, 144. This approach captures all P/S glycans including 
N-, O-, and lipid-linked glycans and breaks them down into monosaccharides that 
maintain linkage information. In short, the method involves the application of glycan 
linkage (methylation) analysis to whole biofluids (Fig. 2.1 and 2.2). Uniquely in this 
approach, linkage-related glycan features are captured and quantified as single 
analytical signals, rather than being spread across numerous intact glycans that bear the 
specific feature. For example, 6-linked galactose and 2,4-linked mannose, 
corresponding to α2-6 sialylation and β1-4 branching, respectively, are both captured 
as single chromatographic peak areas (Fig. 2.1). In addition, many glycan nodes serve 
as direct surrogates for the activities of specific glycosyltransferases (GTs)—enzymes 
that facilitate the construction of glycans. 
Recently, we have applied glycan node analysis to several cancer case-control 
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studies, including pancreatic71, ovarian71, prostate71, bladder72, breast144, and lung71, 74 
cancer cohorts. The purpose of this study was to further validate glycan node analysis 
as a means of detecting and predicting patient outcomes in lung cancer. In addition, 
though glycan node analysis has been analytically validated in the past74, 75, we felt it 
was important to conduct a more comprehensive stability study than that which we have 
previously reported. The cohort of specimens to which we had access that most readily 
lent itself to addressing both of these goals was from a study of lung cancer in women. 
Interestingly, there are several important gender differences in lung cancer, including 
the facts that 1) after adjusting for the number of cigarettes smoked women have a 
three-fold greater risk of lung cancer than men145-148, 2) never-smoker women are at 
significantly greater risk for lung cancer than men149, and 3) women tend to have better 
survival rates than men150, 151. As such, we felt that for any differences observed in this 
study relative to our previously reported results in lung cancer 71, it would also be 
important to look for any existing gender-based differences in glycan nodes as they may 
occur in the context of lung cancer. 
2.2 Materials and Methods 
2.2.1 Materials 
Heavy, stable-isotope-labeled D-glucose (U-13C6, 99%; 1,2,3,4,5,6,6-D7, 97%-
98%) was obtained from Cambridge Isotope Laboratories. Acetone was acquired from 
Avantor Performance Materials (Center Valley, PA). Methanol was purchased from 
Honeywell Burdick & Jackson (Muskegon, Ml). Acetonitrile and methylene chloride 
were obtained from Fisher Scientific (Fair Lawn, NJ). DMSO, iodomethane (99%, Cat. 
No. I8507), chloroform, trifluoroacetic acid (TFA), ammonium hydroxide, sodium 
borohydride, acetic anhydride, sodium acetate and sodium hydroxide beads (20-40 
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mesh, Cat. No. 367176) were acquired from Sigma-Aldrich. Pierce spin colunns (900 
μL volume) were purchased from ThermoFisher Scientific (Waltham, MA, Cat.No. 
69705). GC-MS autosampler vials and Teflon-lined pierceable caps were obtained from 
ThermoFisher Scientific. GC consumables were acquired from Agilent (Santa Clara, 
CA); MS consumables were obtained from Waters (Milford, MA). 
2.2.2 Plasma/Serum Samples 
Women Epidemiology Lung Cancer (WELCA) Set: EDTA plasma samples 
from stage I-IV lung cancer patients and age-matched controls were collected at 12 
different collection centers in France under the supervision of Dr. Isabelle Stücker. This 
study was approved by the Institutional Review Board of the French National Institute 
of Health and Medical Research and by the French data Protection Authority (IRB-
Inserm, no. 3888 and CNIL no. C13-52). As part of the WELCA Study, all-female lung 
cancer patients were recruited between September 2014 and November 2016, and age-
matched all-female controls were recruited between June 2015 and December 2016. 
All women living in Paris and the lle de France area, newly diagnosed with lung cancer 
were considered as eligible cases. Age matched controls were randomly sampled from 
women living in the same area without a history of cancer. All Peripheral blood samples 
were drawn and processed following a written standardized protocol150. Briefly, after 
transport to the laboratory at 4 °C, blood samples collected in tubes containing EDTA 
additive were spun for 15 min at 3000 rpm and 4 °C in a standard centrifuge. Then the 
collected plasma samples were aliquoted and periodically transported in dry ice to the 
central repository for final storage at -80 °C. No freeze-thaw cycles occurred prior to 
shipment to Arizona State University (Borges lab) for analysis. A detailed profile of the 
clinical characteristics of the patients in this WELCA study is given in Table 2.1. 
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Dual Gender Lung Cancer Set: Sodium heparin plasma samples from a lung 
cancer study consisting of patients and controls in both genders were collected by Dr. 
Xifeng Wu at the University of Texas MD Anderson Cancer Center. Even though it is 
a glycosaminoglycan itself, heparin is featured with monomer units that are 
predominately carboxylated, sulfated or both, and thus cannot be directly detected by 
the analytical methodology used in this study. As we have reported previously, there 
are only negligible differences between glycan nodes measure in heparin plasma vs. 
EDTA plasma or serum71, and thus direct comparisons were made for these three types 
of biospecimens. Venous blood samples were collected from newly diagnosed and 
histologically confirmed lung cancer patients prior to therapy at the MD Anderson 
Cancer Center hospital. And the blood samples of age-, gender-, and ethnicity-matched 
controls were collected at the Kelsey-Seybold Clinic. All blood samples were collected 
since 1995 and processed following the same SOP. These specimens has previously 
been described71.  
Stage I Only Lung Cancer Set (also Dual Gender): Serum samples for dual 
gender stage I lung adenocarcinoma patients were collected together with age-, gender-, 
and smoking-status-matched controls, under NYU IRB approval at the NYU Langone 
Medical Center by Dr. Harvey Pass. Arterial blood samples were drawn from fasting 
patients undergoing surgery between September 2006 to August 2013 to remove one 
or more lung nodules that were detected during a CT scan. A pathological exam of the 
excised nodules was performed to determine whether nodules were benign or malignant. 
Serum was collected under a standardized procedure. These specimens have previously 
been described71. 
Additional Biospecimen Details: A summary of the case-control sample sets 
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discussed in this study is provided in Table 2.2. A 300-mL plasma sample from an 
individual donor was obtained from Bioreclamation, which served as a quality control 
sample to ensure batch-to-batch quantitative reproducibility. All specimens were stored 
at -80 °C prior to analysis.  
2.2.3 Experimental Procedures 
The glycan node analysis procedure was adapted from Borges et al74, 75. 
Permethylation, Nonreductive Release, and Purification of Glycans: Nine 
microliters (9 𝜇L) of blood plasma and 1 𝜇L of a 5 mM solution of heavy-labeled D-
glucose (U-13C6, 99%; 1,2,3,4,5,6,6-D7, 97%-98%) and N-acetyl-D-[UL-
13C6]glucosamine were mixed in a 1.5 mL Eppendorf tube, followed by the addition of 
270 𝜇L of DMSO. About 0.7 g sodium hydroxide beads were collected in a Pierce spin 
column (900 𝜇L volume) and washed once with 350 𝜇L of acetonitrile (ACN) followed 
by two rinses with 350 𝜇L of DMSO. The plasma mixed in DMSO solution was added 
to the pre-conditioned NaOH beads in the plugged microfuge spin column, followed by 
adding 105 𝜇L of iodomethane and immediate stirring. After occasional gentle stirring 
the sample solution in NaOH column for 11 min, the microfuge spin column was 
unplugged and spun for 30 s at 5000 rpm (1000 g in a fixed-angle rotor). The collected 
sample solution was quickly transferred into 3.5 mL of 0.5 M NaCl solution in 0.2 M 
sodium phosphate buffer (pH 7) within a silanized 13 ×  100 glass test tube. To 
maximize glycan recovery, the NaOH beads were then washed twice by 300 𝜇L of 
ACN, with all spin-throughs immediately transferred into the same silanized glass test 
tube. To perform liquid/liquid extraction, 1.2 mL of chloroform was added to each test 
tube, which was then capped and shaken well. After brief centrifugation (as above), the 
aqueous layer (top layer) was discarded and then replaced by a fresh aliquot of 3.5 mL 
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of 0.5 M NaCl solution in 0.2 M sodium phosphate buffer (pH 7). With three L/L 
extractions rounds, the chloroform layer was finally extracted and dried under a gentle 
stream of nitrogen at 74 °C. 
Hydrolysis, reduction, and acetylation: To perform TFA hydrolysis, each 
sample was mixed with 2 M TFA (325 𝜇L) and incubated at 121 °C for 2 h, which was 
then dried under a gentle stream of nitrogen at 74 °C. The next step is reduction of sugar 
aldehydes, in which each sample was incubated at room temperature for 1 h after 
dissolution in 475 𝜇 L of freshly made 10 mg/mL sodium borohydride in 1 M 
ammonium hydroxide. To remove excess borate, to each sample 63 𝜇L of methanol 
(MeOH) was added and dried under nitrogen, followed by adding 125 𝜇L of 9:1 (v/v) 
MeOH : acetic acid. Samples were then dried under nitrogen and fully dried in a vacuum 
desiccator for 20 min. The last step is acetylation of nascent hydroxyl groups, in which 
18 𝜇L of deionized water was added to each test tube, thoroughly mixed and sonicated 
for 2 min to dissolve any precipitates. After adding 250 𝜇L of acetic anhydride, each 
sample was incubated for 10 min at 60 °C, followed by mixing with 230 𝜇 L of 
concentrated TFA and incubated again at 60 °C for 10 min. To clean up the sample 
mixture, L/L extraction was performed twice after adding 1.8 mL of dichloromethane 
and 2 mL of deionized water to each test tube. With the aqueous layer (top layer) 
discarded for each round, the organic layer of each sample was then transferred to a 
silanized autosampler vial, dried under nitrogen and reconstituted in 120 𝜇L of acetone, 
which was then capped in preparation for injection onto the GC-MS. 
Gas chromatography-mass spectrometry: An Agilent Model A7890 gas 
chromatograph (equipped with a CTC PAL autosampler) coupled to a Waters GCT 
(time-of-flight) mass spectrometer was employed to analyze the prepared samples. For 
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each sample, 1 𝜇L of the 120 𝜇L total volume was injected onto a hot (280 °C), 
silanized glass liner (Agilent Cat. No. 5183-4647) containing a small plug of silanized 
glass wool at a split ratio of 20:1. A 30-m DB-5ms GC column was used to separate 
different sample components, facilitated by the carrier gas (helium) with a 0.8 mL/min 
flow rate. The GC oven temperature was initially kept at 165 °C for 0.5 min, then 
increased to 265 °C at a rate of 10 °C/min, followed by immediate ramping to 325 °C 
at a rate of 30 °C/min and finally held at 325 °C for 3 min. Sample components eluted 
from GC column were subjected to electron ionization (70 eV, 250 °C). Positive-ion 
mode mass spectra from individual TOF pulses over a m/z range of 40-800 were 
summed every 0.1s. Daily tuning and calibration of the mass spectrometer was 
performed with perfluorotributylamine to ensure reproducible relative abundances of 
EI ions and mass accuracy within 10 ppm. 
2.2.4 Data Analysis 
Quanlynx 4.1 software was employed to integrate the summed extracted-ion 
chromatogram (XIC) peak areas for all glycan nodes. The peak areas were 
automatically integrated and manually verified, then exported to a spreadsheet for 
further analysis.  
Two possible normalization approaches were considered: 1) individual hexoses 
were normalized to heavy glucose, and individual N-acetylhexosamines (HexNAcs) 
were normalized to heavy N-acetyl glucosamine (GlcNAc); 2) individual hexoses were 
normalized to the sum of all endogenous hexoses, and individual HexNAcs were 
normalized to the sum of all endogenous HexNAcs. The second normalization approach 
tends to provide better inter-batch reproducibility (< 9% for the six most elevated 
glycan nodes), but the first approach performs better in identifying the potential 
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increases of all glycan nodes in the patient groups relative to the control group while 
still keeps acceptable average inter-batch %CV (i.e., < 21%). Thus, results reported 
below are based on normalization with heavy glucose and heavy GlcNAc, unless 
otherwise stated. 
For the glycan node data of each cohort, outliers were removed by log-
transformation and the ROUT method at Q = 1% using GraphPad Prism 7. Outlier-
removed data were then reverse transformed by taking the anti-log of each value. To 
identify differences between cohorts, the Kruskal-Wallis test followed by the 
Benjamini-Hochberg false discovery correction procedure was performed at a 5% false 
discovery rate using GraphPad Prism 7.  RStudio Version 1.0.143 was used to compare 
different receiver operating characteristic (ROC) curves by Delong’s test or Bootstrap 
test. The ROC curves shown in figures were plotted by GraphPad Prism 7.  Correlation 
of glycan nodes with age or smoking pack years were assessed via spearman’s rank 
correlation in GraphPad Prism 7. Stage-by-stage multivariate modeling was performed 
using multivariate logistic regression in RStudio Version 1.0.143, with assessment 
carried out by leave-one-out-validation, and model selection done using a best subsets 
procedure. The ability of specific glycan nodes to predict lung cancer survival was 
evaluated with Cox proportional hazards regression model in SAS 9.4. And GraphPad 
Prism 7 was applied to generate survival curves and perform associated log-rank 
Mantel-Cox tests.  
2.3 Results 
2.3.1 Altered Glycan Features in Stage I-IV Patients 
Basic clinical characteristics and n-values of the WELCA sample set were 
described in the Methods section and Table 2.1.  All 207 control and 208 stage I-IV 
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patient samples were randomized and analyzed in 27 batches. Within each control and 
case sample, a total of 19 glycan “nodes” were measured. The relative abundances of 
each of these nodes contributed at least 1% of the total hexose or total N-
acetylhexosamine (HexNAc) signal. Data from each of the 19 glycan nodes were 
normalized to heavy, isotope-labeled glucose and GlcNAc internal standards. 
Statistically significant differences were detected in each cancer stage relative to the 
control cohort: 10, 6, 18 and 19 out of 19 glycan nodes were increased in stage I, II, III 
and IV respectively (Table 2.3).  Data for each glycan node normalized to the sum of 
endogenous hexoses or HexNAcs were analyzed analogously (Table 2.4). This 
revealed shifts in glycan compositions in stage I-IV patients vs. controls.  However, 
because quantitative changes in glycans tended to outpace glycan compositional 
changes (as we have previously observed71) this normalization procedure was not as 
sensitive in distinguishing age-matched controls from lung cancer patients at each stage.  
Six glycan nodes were found to be significantly elevated at nearly every stage 
in lung cancer patients relative to the age-matched controls, these included: 2-linked 
mannose and 4-linked N-acetylglucosamine (GlcNAc), both of which are mostly 
associated with total glycosylation levels especially for N-glycans129; 6-linked 
galactose, corresponding to α2‐6 Sialylation74; 2,4-linked mannose, corresponding to 
β1‐4 Branching74; 2,6-linked mannose, corresponding to β1‐6 Branching74; and 3,4-
linked GlcNAc, which primarily corresponds to outer-arm fucosylation74 (Fig. 2.3). 
The latter four nodes were amongst the top five most elevated nodes in our previously 
reported lung cancer study71. The receiver operating characteristic (ROC) curve c-
statistics (areas under the curve, AUCs) for these six glycan nodes in stage I-IV patients 
vs. controls ranged (with two exceptions) from 0.68 to 0.92 (Fig. 2.3). 
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2.3.2 Prominent Early-Stage Alteration 
Relative to the age-matched controls, five of the six top performing glycan node 
markers in stage I patients, and four in stage II patients, were significantly increased 
(Fig. 2.3). In addition, the ROC c-statistics (AUC) of these glycan nodes were mostly 
statistically significant and ranged from 0.68 to 0.80 (with one exception). The notable 
alterations of glycan nodes in early stages were usually not observed for other lung 
cancer sets, such as the dual gender lung cancer set and stage I only lung cancer set 
(which was also dual-gender) reported in our previous work71 (n-values for these 
studies provided in Table 2.2). ROC curves of these three lung cancer sets were 
compared (Table 2.5) and shown in Fig. 2.4. Significant differences were observed for 
β1‐6 branching when the ROC curve of the stage I cohort of the WELCA set was 
compared to that of the stage I only lung cancer set and that of the stage I cohort of the 
dual gender lung cancer set. When comparing ROC curves for the stage IV cohorts of 
the WELCA set and the dual gender lung cancer set, significant differences were found 
for three glycan features--i.e., α2‐6 sialylation, β1‐4 and β1‐6 branching. Since all the 
lung cancer patients and age-matched controls involved in the WELCA set were female, 
the gender dependence of these glycan node markers in early stages was evaluated in 
the other two lung cancer sets, which included patients and controls from both sexes. 
When sample set and stage were held constant, the ROC curves of two sexes were 
compared for each glycan node using Delong’s test or the Bootstrap test (Table 2.6). 
No significant differences were observed, however, indicating the early-stage clinical 
performance characteristics of the six glycan node markers were independent of gender. 
2.3.3 Negligible dependence on smoking-status, age and histological type 
No significant alteration of five out of the six top performing glycan node 
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markers was observed in a direct comparison of never-smokers, previous smokers and 
current smokers within the control cohort. The only exception was 3,4-linked GlcNAc 
(corresponding to outer-arm fucosylation), which was slightly elevated in current 
smokers relative to previous smokers (Fig. 2.5). Spearman’s rank correlation analysis 
demonstrated no statistically significant correlation with smoking pack-years in the 
control cohort. Together, these data revealed that the top performing glycan node 
markers within the control cohort had negligible dependence on smoking status. (A 
parallel analysis within the cancer patient cohort was not conducted due to the 
confounding correlation between smoking and lung cancer.) 
The average ages of the control and case cohorts were nearly identical (61.2 and 
61.6, respectively; Table 2.1). After pooling all data from the cases (all stages) and 
controls, 3,4-linked GlcNAc, corresponding to outer-arm fucosylation, was found to be 
weakly correlated with age (correlation coefficient r = 0.159, Bonferroni-corrected p = 
0.0096; Fig. 2.6a). No statistically significant correlations with age were observed for 
the other five top performing glycan nodes (Table 2.7). When the population was 
divided into smaller age groups, only 3,4-linked GlcNAc showed significant 
differences between pairs of decades; if the control and case cohorts were investigated 
in isolation, 3,4-linked GlcNAc within the controls in particular indicated a distinct 
upward pattern in more advanced age groups (Fig. 2.6b). The same phenomenon was 
observed in the male-only controls of the dual gender lung cancer set. However, with 
the exception of 3,4-GlcNAc, these analyses indicated a general lack of dependence of 
glycan node markers on age.  
The effect of lung cancer histological subtypes on the six glycan nodes was 
evaluated in the stage IV non-small cell lung cancer (NSCLC) subcohort (i.e., the 
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largest single-stage subcohort available; Table 2.1). For each glycan node marker, ROC 
curves of the three histological subtypes of NSCLC – adenocarcinoma, squamous cell 
carcinoma, and large cell carcinoma – were compared pairwise by Delong’s test or 
Bootstrap test (Table 2.8). No statistically significant differences between histological 
subtypes of NSCLC were discovered for any glycan node marker. 
These findings on glycan node independence from smoking status, age and 
histological type are consistent with our previously reported findings from other lung 
cancer case/control studies71. 
2.3.4 Total Glycosylation and Multivariate Model of glycan features 
The clinical performance characteristics of total glycosylation (i.e., total 
hexoses, total HexNAcs, and the sum of total hexoses & total HexNAcs) were evaluated 
and compared to individual glycan node markers on a stage-by-stage basis (Table 2.9). 
Results of ROC curve comparisons by paired Delong’s tests demonstrated that total 
glycosylation cannot distinguish stage I-IV cases from controls better than individual 
glycan node markers. 
Additionally, multivariate logistic regression models were built and compared 
with the clinical performance characteristics of individual glycan nodes at each stage 
(Fig. 2.7). Fully cross-validated multivariate logistic regression models were no better 
at detecting lung cancer than the top-performing individual glycan node at each 
respective stage. Again, these results were consistent with our previous observations in 
lung cancer71. 
2.3.5 Prediction of All-Cause Mortality 
To evaluate the ability of the six glycan nodes to predict all-cause mortality, 
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glycan node data were broken into quartiles and analyzed by Cox proportional hazards 
regression, with adjustment for age, smoking status, and cancer stage (Table 2.10). 
First and foremost, for patients in all four stages, the top quartiles of all six glycan node 
markers predicted all-cause mortality with hazard ratios in the range of 2-3 and p < 0.01, 
relative to all other quartiles combined. The different rates of death for the top quartile 
versus all other quartiles for each glycan node marker are illustrated by survival curves 
(Fig. 2.8).  
When focusing on stage III and IV patients, the top quartiles of all six glycan 
node markers predicted all-cause mortality with hazard ratios in the range of 2-3 and p 
< 0.05 (Table 2.10) relative to all other quartiles combined (survival curves shown in 
Fig. 2.9). Similar results were observed for stage IV patients only (Table 2.10). 
However, when stage III patients were analyzed alone, the hazard ratios of all six glycan 
nodes were not significantly different from 1 (p > 0.05), indicating the relative risk of 
death was not detectably different between patients in the top quartile vs. all other 
quartiles of each glycan node. 6-linked galactose (corresponding to α2‐6 Sialylation) 
and 2,4-linked mannose (corresponding to β1‐4 Branching), were significantly different 
between stages III and IV (Fig. 2.3 b,c). 
Overall, these results for glycan node-based prediction of mortality vary slightly, 
but are largely consistent with our previously reported results on the ability of α2-6 
sialylation and branched mannose residues to predict all-cause mortality in lung cancer. 
2.4 Discussion 
Six out of 19 quantified glycan nodes, corresponding to total glycosylation 
levels (especially for N-glycans), α2‐6 Sialylation, β1‐4 Branching, β1‐6 Branching and 
outer-arm fucosylation, were significantly elevated in the WELCA lung cancer patients 
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relative to age-matched controls. Most of these findings in the WELCA set are highly 
consistent with our previously reported lung cancer study on a dual gender lung cancer 
set71, which also demonstrated the distinct increase of the latter four glycan features 
within stage III-IV cases compared to the control cohort. 
Our observations of the glycan node-based features changes in lung cancer 
patients are closely aligned with the intact glycan changes reported by Vasseur and 
colleagues69. Their intact glycan analysis results primarily revealed the significant 
increase of outer-arm fucosylation, as well as fucosylated tri- and tetra-antennary N-
glycans, in line with β1‐4 branching, β1‐6 branching, in lung cancer samples.  
Unlike the other two lung cancer sets that we have reported on previously71, 
some glycan node-based features were substantially altered in the WELCA lung cancer 
patients at stages I-II (Fig. 2.4). Even though a relatively low number of samples were 
measured for early stages (n = 16 and 13 for stage I and II, respectively), statistically 
significant elevations were detected in most of the six glycan node markers, alongside 
comparatively high ROC c-statistics. There are two possible causes for this 
phenomenon. First, since the lung cancer patients and controls enrolled in the WELCA 
study are all female, a distinct gender dependence of glycan features may exist, 
especially in early stages. However, this possibility is not evidenced by the observation 
that no significant difference was detected between men and women in stage I and II of 
the dual gender lung cancer set, as well as in the stage I only lung cancer set—which 
was also dual gender (Table 2.6). The second possible explanation is that the non-
smoking-matched controls of the WELCA set may have much lower relative 
abundances of all the glycan nodes of interest relative to the smoking-matched controls 
from other lung cancer sets. In the WELCA set most controls were never-smokers, but 
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case patients are mainly current-smokers (Table 2.1), indicating that the smoking 
history possibly contributes to the increase of glycan nodes. Taken together the 
observations of the WELCA set that the top performing glycan node markers within 
the control cohort had negligible dependence on smoking status (Fig. 2.6), smoking 
appears to contribute to slight, but statistically insignificant elevation of glycan nodes. 
The six top performing glycan nodes-based features in this study were not only 
able to distinguish lung cancer patients from age-matched controls, but were also able 
to predict all-cause mortality in the WELCA set—a finding that agrees well with our 
previously reported study on the dual gender lung cancer set71. Similar discoveries 
regarding the prognostic capacity of P/S glycans have also been reported by other 
groups. Hashimoto and colleagues152 suggested that specific glycoforms of serum α1-
acid glycoprotein (AGP) seemed to appropriately predict progression and mortality of 
several carcinomas, including lung cancer. According to their follow-up studies, 
patients who had the AGP glycoforms that contained highly fucosylated and branched 
sugar chains tended to have a poor prognosis. Besides the glycan features discussed 
above, another good prognostic predictor of lung cancer is the sialyl Lewis X epitope 
(SLex)153, which consists of α2-3 sialylation instead of α2-6 sialylation. The progression 
and survival in non-small-cell154-156 and small-cell lung cancer157 can both be predicted 
by SLex. 
Many studies have reported important gender differences in lung cancer 
between men and women, in terms of histological type, tobacco exposure, survival and 
treatment response158, 159. Here, by comparison with our previously conducted studies71 , 
no obvious gender differences were detected with regard to P/S glycan features. 
Smoking is the primary risk factor for lung cancer. However, a large percentage of 
41 
women with lung adenocarcinoma, between 20% and 30% in Western countries and 
nearly 80% in Asian countries, are non-smokers150. Hence, some female-specific risk 
factors for lung cancer exist and may play vital roles in lung cancer development, 
progression and survival; these may include hormonal factors and occupational risk 
factors in female occupations—as suggested by Stucker et al150. Therefore, studies 
focused on lung cancer in women, especially on the gender specific risk factors, should 
garner further attention as they promise to disentangle the etiology of lung cancer in 
women. 
2.5 Conclusion 
The diagnostic and prognostic capacity of plasma glycan features in stage I-IV 
lung cancer—as represented by monosaccharide and linkage-specific glycan nodes—
were validated in the WELCA case-control study. Significant elevation of α2‐6 
sialylation, β1‐4 branching, β1‐6 branching, outer‐arm fucosylation and total N-
glycosylation level, were observed in almost every stage of lung cancer relative to age-
matched control groups. Alteration of glycan features in lung cancer was independent 
of smoking status, age and histological subtypes of lung cancer. Furthermore, the above 
six glycan features predicted all-cause mortality in lung cancer patients after adjusting 
for age, smoking status, and cancer stage. Early-stage detection was stronger than we 
have previously observed71, but this observation may have been related to the lack of 
smoking status-matching between cases and controls in the WELCA study. No gender-
based differences were discovered in glycan features associated with lung cancer.   
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Figures 
 
Figure 2.1. Conceptual overview of the glycan “node” analysis concept, which 
essentially consists of applying glycan linkage (methylation) analysis to whole 
biofluids. Intact normal and abnormal glycans including O-glycans, N-glycans, and 
glycolipids are processed and transformed into partially methylated alditol acetates 
(PMAAs, Figure 2.2), each of which corresponds to a particular monosaccharide-and-
linkage-specific glycan “node” in the original polymer. As illustrated, analytically 
pooling together the glycan nodes from among all the aberrant intact glycan structures 
provides a moredirect surrogate measurement of abnormal glycosyltransferase activity 
than any individual intact glycan while simultaneously converting unique glycan 
features such as “core fucosylation”, “α2−6 sialylation”, “bisecting GlcNAc”, and 
“β1−6 branching” into single analytical signals. Actual extracted ion chromatograms 
from 9 μL blood plasma samples are shown. Numbers adjacent to monosaccharide 
residues in glycan structures indicate the position at which the higher residue is linked 
to the lower residue. This figure was adapted with permission from Borges et al.74. 
Copyright 2013 American Chemical Society. 
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Figure 2.2. Molecular overview of the glycan “node” analysis procedure. For glycans 
from blood plasma and other biofluids, O-linked glycans are released during 
permethylation, while N-linked glycans and glycolipids are released during acid 
hydrolysis. The unique pattern of methylation and acetylation in the final partially 
methylated alditol acetates (PMAAs) corresponds to the unique “glycan node” in the 
original glycan polymer and provides the molecular basis for separation and 
quantification by GC-MS. Figure adapted with permission from Borges et al.74. 
Copyright 2013 American Chemical Society. 
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Figure 2.3. Univariate distribution (a-f) and ROC curves (g-l) for the six top 
performing glycan nodes in the WELCA study. The Kruskal−Wallis test was 
performed followed by the Benjamini−Hochberg false discovery correction 
procedure. The letters at the top of data points in panels a-f demonstrate statistically 
significant differences between groups; any overlap in letters indicates a lack of 
significant differences between groups. ROC curves for stage I-IV lung cancer cases 
vs. controls are provided in panels g-l. Areas under the ROC curves are provided in 
parenthesis next to the specified stages. “NS” next to the AUC values indicates that 
the ROC curve is not statistically significant. All raw glycan node data in this figure 
were normalized to heavy glucose or heavy GlcNAc prior to data analysis. 
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Figure 2.4. ROC curves for four top performing glycan nodes in stage I-IV within 
different lung cancer sets. Four glycan nodes with highly-ranked performance in all 
three sample sets were shown. The ROC curves from WELCA sample set are illustrated 
in panels a-d. In panels e-i are ROC curves from the other two lung cancer sets: Dual 
Gender Lung Cancer set (e-h) and Stage I Only Lung Cancer set (also dual gender). N-
values of each group are provided in Table 2.2. 
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Figure 2.5. Connection between outer-arm fucosylation and smoking status within the 
control group. (a) The univariate distributions of outer-arm fucosylation within the 
control group are shown, subdivided by smoking status. Different letters above the data 
points indicate statistically significant differences between groups as detected by the 
Kruskal-Wallis test followed by the Benjamini-Hochberg FDR correction procedure. 
(b) Spearman’s rank correlation between outer-arm fucosylation and smoking pack-
years. Correlation coefficient is provided above the data points. “NS” next to the 
correlation coefficient demonstrates a lack of statistical significance. For the other five 
top performing glycan nodes not shown in this figure, no statistically significant 
associations with smoking were found. 
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Figure 2.6. Connection between age and a top performing glycan node, 3,4-linked 
GlcNAc, in the WELCA study. (a) Spearman’s rank correlation coefficients are 
provided above the data points. “**” next to the coefficient indicates that the 
Spearman’s rank correlation was statistically significant with Bonferroni-corrected p < 
0.01. Controls are indicated by black triangles and cases by red dots. (b) The 
Kruskal−Wallis test was performed followed by the Benjamini−Hochberg false 
discovery correction procedure to identify difference between age groups. The letters 
at the top of bars demonstrate statistically significant differences between groups; any 
overlap in letters indicates a lack of significant differences between groups. For the 
other five top performing glycan nodes not shown in this figure, no statistically 
significant associations with age were found. 
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Figure 2.7. Multivariate logistic regression models for stage I−IV patients from the 
WELCA data set. Three multivariate logistic regression models were built and 
corresponding ROC curves were plotted for each stage with different fitting procedures: 
(1) fitted once on the complete data set and acquired probability (referred to as “Fitted 
Probabilities”) with no use of cross-validation; (2) fitted once on the complete data set, 
cross-validated with fixed predictors but mobile parameter estimates at each iteration 
(predicted probability referred to as “CV Probabilities (semi)”); and (3) refitted at each 
iteration of cross-validation (corresponding probability demonstrated as “CV 
Probabilities (full)”). ROC AUC values are provided in parenthesis next to the specified 
models. For each stage, the best performing individual glycan node was selected and 
compared to the fully validated multivariate model. No significant differences were 
detected (Delong’s test).   
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Figure 2.8. Survival curves for the six top performing glycan nodes for all stages 
combined. In each panel, the top quartile of specified glycan node is compared to all 
other quartiles combined. According to results of log-rank Mantel-Cox test, the survival 
curves within each panel are significantly different (p < 0.0001). Dotted lines represent 
95% confident intervals. The median duration of follow-up for deceased patients (until 
death) was 406 days; for those that remained alive it was 1253 days. The median follow-
up time for all patients was 1057 days. 
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Figure 2.9. Survival curves of the six top performing glycan nodes for stage III and IV 
combined. In each panel, the top quartile of specified glycan node is compared to all 
other quartiles combined. According to the results of a log-rank Mantel-Cox test, the 
survival curves within each panel are significantly different (p < 0.05). Dotted lines 
represent 95% confident intervals. The median duration of follow-up for patients that 
died, until death, was 393 days; for survivors this value was 1264 days. The median 
total follow-up time for all patients was 908 days.  
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Tables 
Table 2.1. Basic Clinical Characteristics and N-values of the WELCA Sample Set. 
 WELCA set 
Controls Cases 
Agea  61.2 ± 9.73 61.6 ± 9.04 
Smoking Status Never-Smoker 90 36 
Previous-Smoker 72 52 
Current-Smoker 45 98 
Unknown 0 22 
Staging Stage I N/A 16 
Stage II N/A 13 
Stage III N/A 45 
Stage IV N/A 99 
Unknown Stage N/A 35 
Tumor Histological 
Types 
SCLC – Located N/A 7 
SCLC - Disseminated N/A 12 
NSCLC - Adenocarcinoma N/A 131 
NSCLC - Squamous cell 
carcinoma 
N/A 25 
NSCLC - Large cell 
carcinoma 
N/A 13 
NSCLC - Adenosquamous N/A 1 
NSCLC - Sarcoma N/A 3 
Unknown N/A 16 
aAge in years ± SD. 
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Table 2.2. Composition of Three Lung Cancer Sample Sets and Their Sub-
cohorts. 
Name of Sample Set Plasma or Serum 
Controls 
(M/F) 
Stage I 
(M/F) 
Stage 
II 
(M/F) 
Stage 
III 
(M/F) 
Stage 
IV 
(M/F) 
WELCA set plasma 0/207 0/16 0/13 0/45 0/99 
Dual Gender Lung 
Cancer set plasma 123/76 14/6 12/8 50/31 47/31 
Stage I Only Lung 
Cancer set serum 28/45 33/74 ‒ ‒ ‒ 
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Table 2.3. Statistically Significant Differences between Cohorts within the 
WELCA Studya 
glycan nodeb C vs I C vs II 
C vs 
III 
C vs 
IV I vs II 
I vs 
III 
I vs 
IV 
II vs 
III 
II vs 
IV 
III vs 
IV 
t-Fucose ns ns iiii iiii ns ns ns ns ns ns 
t-Gal ii ns iiii iiii ns ns ns ns i ns 
2-Man iii i iiii iiii ns ns ns ns i ns 
4-Glc iii i iiii iiii ns ns ns ns ns ns 
3-Gal ns ns ns iiii ns ns ns ns iii ii 
6-Gal ii ns iiii iiii ns ns i ns ii i 
3,4-Gal ii ii iiii iiii ns ns ns ns ns ns 
2,4-Man i i iiii iiii ns ns iii ns ii ii 
2,6-Man iii ii iiii iiii ns ns ns ns ns ns 
3,6-Man ns ns ii iiii ns ns ns i iii i 
3,6-Gal ns ns i iiii ns ns ns ns iii ii 
3,4,6-Man ii ns ii ii i ns ns ns ns ns 
t-GlcNAc ns ns iiii ii ns ns ns ii ns ns 
4-GlcNAc ii ns iiii iiii ns ns i i ii ns 
3-GlcNAc ns ns iiii iiii ns ns ns ns ns ns 
3-GalNAc ns ns ii iiii ns ns ns ns ns ns 
3,4-GlcNAc ns ii iiii iiii ns i ii ns ns ns 
4,6-GlcNAc iii ns iiii iiii ii ns ns ii ii ns 
3,6-GalNAc ns ns ii iiii ns ns ns ns ns ns 
 
aHeavy, stable isotope labeled glucose (Glc) and GlcNAc were utilized to normalize 
Hexose and HexNAc data, correspondingly.  
bKruskal-Wallis test followed by Benjamini−Hochberg false discovery correction 
procedure at 95% confidence level is given. “ns” stands for “not significant”. “i” 
indicates p < 0.05. “ii” indicates p < 0.01. “iii” indicates p < 0.001, and “iiii” indicates 
p < 0.0001. C: controls; I: Stage I; II: Stage II; III: Stage III; IV: Stage IV. 
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Table 2.4. Statistically Significant Differences between Cohorts within the 
WELCA Study (by Endogenous Normalization a). 
Glycan 
Nodeb 
C vs 
I 
C vs 
II 
C vs 
III 
C vs 
IV 
I vs 
II 
I vs 
III 
I vs 
IV 
II vs 
III 
II vs 
IV 
III vs 
IV 
t-Fucose ns ns ns ns ns ns ns ns ns ns 
t-Gal ns ns dddd dddd ns dd ns ns ns ns 
2-Man ns ns ns dd ns ns ns ns d d 
4-Glc ns ns ns ns ns ns ns ns ns ns 
3-Gal ns dd dd ns ns ns ns ns ns ns 
6-Gal ns ns i iiii ns ns ii ns ns ns 
3,4-Gal ns ns ns ns ns ns ns ns ns ns 
2,4-Man ns ns ii iiii ns ns iiii ns ns iiii 
2,6-Man ns ii iii iiii ns ns ns ns ns ns 
3,6-Man ns dd ns ns dd ns ns ns ii ns 
3,6-Gal ns dd ns ns ns ns ns ns ii ns 
3,4,6-Man ns dd ddd dddd d ns ddd ns ns dd 
t-GlcNAc ns d dd dddd ns ns ddd ns ns ddd 
4-GlcNAc ns ns ns iiii ns ns ns ns ns ns 
3-GlcNAc ns ns ns ns ns ns ns ns ns ns 
3-GalNAc ns ns dddd dddd ns ns dd ns ns ns 
3,4-GlcNAc ns ii iiii iiii i i ii ns ns ns 
4,6-GlcNAc ns d dd dddd dd dd dddd ns ns d 
3,6-GalNAc ns ns dd dddd ns ns ns ns ns ns 
 
aHexose data were normalized to the sum of endogenous hexoses, and HexNAc data 
were normalized to the sum of endogenous HexNAcs. 
bKruskal-Wallis test followed by Benjamini−Hochberg false discovery correction 
procedure at 95% confidence level is given. “ns” stands for “not significant”. “i” and 
“d” stands for “increased” and “decreased”. i/d indicates p < 0.05. ii/dd indicates p < 
0.01. iii/ddd indicates p < 0.001, and iiii/dddd indicates p < 0.0001. C: controls; I: Stage 
I; II: Stage II; III: Stage III; IV: Stage IV. 
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Table 2.5. Stage-by-stage ROC Comparison of the Top Performing Glycan 
Nodes.  
Stagesa Glycan Feature A: ROC AUC of set A B: ROC AUC of set B 
p-value of Delong’s test 
for two ROC curvesb 
Stage I 
 
Set A: WELCA Set 
Set B: Stage I Only 
Lung Cancer Set 
α2‐6 Sialylation A: 0.733 0.031 (NS) B: 0.564 
β1‐4 Branching A: 0.696 0.112 (NS) B: 0.549 
β1‐6 Branching A: 0.797 0.008 B: 0.592 
Outer‐Arm Fucosylation A: 0.609 0.965 (NS) B: 0.613 
Stage I 
 
Set A: WELCA Set 
Set B: Dual Gender 
Lung Cancer Set 
α2‐6 Sialylation A: 0.733 0.092 (NS) B: 0.575 
β1‐4 Branching A: 0.696 0.264 (NS) B: 0.579 
β1‐6 Branching A: 0.797 0.008 B: 0.547 
Outer‐Arm Fucosylation A: 0.609 0.885 (NS) B: 0.594 
Stage II 
 
Set A: WELCA Set 
Set B: Dual Gender 
Lung Cancer Set 
α2‐6 Sialylation A: 0.681 0.509 (NS) B: 0.607 
β1‐4 Branching A: 0.707 0.489 (NS) B: 0.630 
β1‐6 Branching A: 0.770 0.071 (NS) B: 0.582 
Outer‐Arm Fucosylation A: 0.760 0.302 (NS) B: 0.655 
Stage III 
 
Set A: WELCA Set 
Set B: Dual Gender 
Lung Cancer Set 
α2‐6 Sialylation A: 0.796 0.241 (NS) B: 0.739 
β1‐4 Branching A: 0.798 0.407 (NS) B: 0.755 
β1‐6 Branching A: 0.822 0.119 (NS) B: 0.745 
Outer‐Arm Fucosylation A: 0.826 0.161 (NS) B: 0.754 
Stage IV 
 
Set A: WELCA Set 
Set B: Dual Gender 
Lung Cancer Set 
α2‐6 Sialylation A: 0.887 0.009 B: 0.791 
β1‐4 Branching A: 0.917 0.002 B: 0.802 
β1‐6 Branching A: 0.907 0.008 B: 0.810 
Outer‐Arm Fucosylation A: 0.822 0.307 (NS) B: 0.777 
aThe WELCA set was compared to the Dual Gender Lung Cancer Set and Stage I Only 
Lung Cancer Set (also dual gender). N-values of each group are shown in Table 2.2. 
Actual ROC curves are shown in Fig. 2.4.  
b“NS” indicates no significant difference between the two compared ROC curves. The 
significant levels of p values are adjusted by Bonferroni multiple comparison correction: 
p > 0.013 (NS), p < 0.013 (*), p < 0.003 (**), p < 0.0003 (***). 
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Table 2.6. Comparison of Top Performing Glycan Nodes in Male vs. Female 
Patients with Early Stage Lung Cancer.  
Lung Cancer Setsa Glycan Feature A: ROC AUC of set A B: ROC AUC of set B 
p-value of Delong’s test for 
two ROC curvesb 
Dual Gender Lung Cancer 
Set 
Stage I 
Male vs Female 
 
Set A: 
Male Patients (n = 14) 
vs Male Controls (n = 123) 
Set B: 
Female Patients (n = 6) 
vs  Female Controls (n = 76) 
2-linked Mannose A: 0.618 0.537 (NS) B: 0.544 
α2‐6 Sialylation A: 0.646 0.393 (NS) c B: 0.553 
β1‐4 Branching A: 0.629 0.464 (NS) c B: 0.539 
β1‐6 Branching A: 0.598 0.870 (NS) c B: 0.579 
4-linked GlcNAc A: 0.592 0.686 (NS) B: 0.537 
Outer‐Arm Fucosylation A: 0.552 0.206 (NS) B: 0.702 
Dual Gender Lung Cancer 
Set 
Stage II 
Male vs Female 
 
Set A: 
Male Patients (n = 12) 
vs Male Controls (n = 123) 
Set B: 
Female Patients (n = 8) 
vs  Female Controls (n = 76) 
2-linked Mannose A: 0.628 0.719 (NS) B: 0.579 
α2‐6 Sialylation A: 0.626 0.873 (NS) B: 0.602 
β1‐4 Branching A: 0.633 0.918 (NS) B: 0.618 
β1‐6 Branching A: 0.594 0.826 (NS) B: 0.559 
4-linked GlcNAc A: 0.648 0.533 (NS) B: 0.564 
Outer‐Arm Fucosylation A: 0.737 0.382 (NS) B: 0.615 
Stage I Only Lung Cancer Set 
Male vs Female 
 
Set A: 
Male Patients (n = 33) 
vs Male Controls (n = 28) 
Set B: 
Female Patients (n = 74) 
vs  Female Controls (n = 45) 
2-linked Mannose A: 0.655 0.247 (NS) B: 0.547 
α2‐6 Sialylation A: 0.585 0.766 (NS) B: 0.557 
β1‐4 Branching A: 0.448 0.219 (NS) c B: 0.563 
β1‐6 Branching A: 0.450 0.0825 (NS) c B: 0.616 
4-linked GlcNAc A: 0.650 0.508 (NS) B: 0.589 
Outer‐Arm Fucosylation A: 0.632 0.811 (NS) B: 0.610 
aComparisons are made for stage I and II of the Dual Gender Lung Cancer Set, and the 
Stage I Only Lung Cancer Set. Unpaired Delong’s test or Bootstrap test are applied to 
compare two ROC curves.  
b“NS” indicates no significant difference between the two compared ROC curves. The 
significant levels of p values are adjusted by Bonferroni multiple comparison correction: 
p > 0.0083 (NS), p < 0.0083 (*), p < 0.0017 (**), p < 0.00017 (***). 
cp-value is from Bootstrap test instead of Delong’s test, because Delong’s test should 
not be applied to ROC curves with different directions and the stratification of 
Bootstrap is especially useful if groups are not balanced. 
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Table 2.7. Correlation Between Age and the Top Performing Glycan Nodes in 
the WELCA Cases (All stages) and, Separately, Controls.   
Case/Controla Glycan Feature Correlation coefficient (r) 
p-value of 
Spearman’s rank 
correlationb 
Case 
 
n = 208 
2-linked Mannose 0.102 0.168 (NS) 
α2‐6 Sialylation 0.073 0.324 (NS) 
β1‐4 Branching 0.072 0.329(NS) 
β1‐6 Branching 0.091 0.217 (NS) 
4-linked GlcNAc 0.030 0.681 (NS) 
Outer‐Arm 
Fucosylation 
0.148 0.044 (NS) 
Control 
 
n = 207 
2-linked Mannose 0.039 0.577 (NS) 
α2‐6 Sialylation 0.075 0.283 (NS) 
β1‐4 Branching 0.047 0.501 (NS) 
β1‐6 Branching 0.103 0.142(NS) 
4-linked GlcNAc -0.101 0.148 (NS) 
Outer‐Arm 
Fucosylation 
0.205 0.0031 
aSpearman's rank correlation coefficients and p values are provided for the six top 
performing glycan features in all cases (n = 208) and controls (n = 207).   
b“NS” indicates no significant correlation between age and the corresponding glycan 
feature. The significant levels of p values are adjusted by Bonferroni multiple 
comparison correction: p > 0.0083 (NS), p < 0.0083 (*), p < 0.0017. 
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Table 2.8. Comparison of the Top Performing Glycan Nodes in Different 
Histological Types.  
Histological Typesa Glycan Feature 
A: ROC AUC of set 
A 
B: ROC AUC of set 
B 
p-value of Delong’s 
test for two ROC 
curvesb 
Adenocarcinoma 
vs 
Squamous cell 
carcinoma 
 
Set A: Adenocarcinoma 
vs Controls 
Set B: Squamous cell 
carcinoma vs Controls 
2-linked Mannose A: 0.854 0.071 (NS) c B: 0.926 
α2‐6 Sialylation A: 0.878 0.130 (NS) c B: 0.939 
β1‐4 Branching A: 0.908 0.114 (NS) c B: 0.960 
β1‐6 Branching A: 0.906 0.539 (NS) c B: 0.939 
4-linked GlcNAc A: 0.877 0.702 (NS) c B: 0.899 
Outer‐Arm 
Fucosylation 
A: 0.815 
0.608 (NS) c B: 0.861 
Adenocarcinoma 
vs 
Large cell carcinoma 
 
Set A: Adenocarcinoma 
vs Controls 
Set B: Large cell 
carcinoma vs Controls 
2-linked Mannose A: 0.854 0.957 (NS) c B: 0.860 
α2‐6 Sialylation A: 0.878 0.647 (NS) c B: 0.817 
β1‐4 Branching A: 0.908 0.586 (NS) c B: 0.828 
β1‐6 Branching A: 0.906 0.402 (NS) c B: 0.808 
4-linked GlcNAc A: 0.877 0.934 (NS) c B: 0.869 
Outer‐Arm 
Fucosylation 
A: 0.815 
0.706 (NS) c B: 0.757 
Squamous cell 
carcinoma 
vs 
Large cell carcinoma 
 
Set A: Squamous cell 
carcinoma vs Controls 
Set B: Large cell 
carcinoma vs Controls 
2-linked Mannose A: 0.926 0.556 (NS) B: 0.860 
α2‐6 Sialylation A: 0.939 0.406 (NS) B: 0.817 
β1‐4 Branching A: 0.960 0.426 (NS) B: 0.828 
β1‐6 Branching A: 0.939 0.332 (NS) B: 0.808 
4-linked GlcNAc A: 0.899 0.804 (NS) B: 0.869 
Outer‐Arm 
Fucosylation 
A: 0.861 
0.578 (NS) B: 0.757 
aComparisons are made for stage IV patients with various histological types of non-small cell 
lung cancer (NSCLC) vs. all controls. The n-values for the different histological sets are as 
following. Adenocarcinoma set: n = 70; Squamous cell carcinoma set: n = 8; Large cell 
carcinoma set: n = 5; Controls: n = 207. Unpaired Delong’s test or Bootstrap test are used to 
compare two ROC curves.  
b“NS” indicates no significant difference between the two compared ROC curves. The 
significant levels of p values are adjusted by Bonferroni multiple comparison correction: p > 
0.0083 (NS). 
cp-value is from Bootstrap test instead of Delong’s test, because the stratification of Bootstrap 
is especially useful if groups are not balanced. 
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Table 2.9. Stage-by-stage Comparison of Total Glycosylation with Individual 
Glycan Feature.  
Stagesa Glycan Feature ROC AUC p-value of Delong’s test for two ROC curvesb 
Stage I 
A β1‐6 Branching 0.797 
A vs B: 0.280 (NS) 
 
A vs C: 0.196 (NS) 
 
A vs D: 0.289 (NS) 
B Total Hexoses 0.750 
C Total HexNAcs 0.730 
D Total Hexoses and HexNAcs 0.755 
Stage II 
A β1‐6 Branching 0.770 
A vs B: 0.024 (NS) 
 
A vs C: 0.091 (NS) 
 
A vs D: 0.017 
B Total Hexoses 0.674 
C Total HexNAcs 0.627 
D Total Hexoses and HexNAcs 0.679 
Stage III 
A 2-linked Mannose 0.843 
A vs B: 0.938 (NS) 
 
A vs C: 0.676 (NS) 
 
A vs D: 0.196 (NS) 
B Total Hexoses 0.844 
C Total HexNAcs 0.830 
D Total Hexoses and HexNAcs 0.860 
Stage IV 
A β1‐4 Branching 0.917 
A vs B: 0.021 (NS) 
 
A vs C: 0.159 (NS) 
 
A vs D: 0.280 (NS) 
B Total Hexoses 0.892 
C Total HexNAcs 0.891 
D Total Hexoses and HexNAcs 0.907 
aFor each stage, the individual top performing glycan node with the largest area under 
curve (AUC) value was selected to compare to total hexoses (sum of all hexose glycan 
nodes), total HexNAcs (sum of all HexNAc glycan nodes) and total Hexoses and 
HexNAcs (sum of all glycan nodes). A paired Delong’s test was utilized to compare 
two ROC curves.  
b“NS” indicates no significant difference between the two compared ROC curves. The 
significant levels of p values are adjusted by Bonferroni multiple comparison correction: 
p > 0.017 (NS), p < 0.017 (*), p < 0.0033 (**). 
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Table 2.10. Survival Prediction by the Top Performing Glycan Nodes in All Stages, 
Stage III and IV Combined, Stage III Only and Stage IV Only. 
Stage Involved Glycan Feature 
Cox proportional hazards regression modela 
p-valueb Hazard Ratio Lower bound at 95% CL 
Upper bound 
at 95% CL 
All stages 
 
n = 197 
2-linked Mannose 0.0003 2.39 1.49 3.83 
α2‐6 Sialylation 0.0002 2.48 1.53 4.03 
β1‐4 Branching < 0.0001 2.70 1.66 4.41 
β1‐6 Branching 0.0002 2.54 1.57 4.12 
4-linked GlcNAc 0.0066 1.99 1.21 3.26 
Outer‐Arm 
Fucosylation 
< 0.0001 2.75 1.70 4.42 
Stage III & IV 
 
n = 138 
2-linked Mannose 0.0059 2.09 1.24 3.52 
α2‐6 Sialylation 0.0029 2.16 1.30 3.58 
β1‐4 Branching 0.0014 2.29 1.38 3.82 
β1‐6 Branching 0.0014 2.29 1.38 3.82 
4-linked GlcNAc 0.0148 (NS) 1.98 1.14 3.42 
Outer‐Arm 
Fucosylation 
0.0011 2.45 1.43 4.18 
Stage III 
 
n = 44 
2-linked Mannose 0.3291 (NS) 1.69 0.59 4.81 
α2‐6 Sialylation 0.1551 (NS) 2.12 0.75 5.99 
β1‐4 Branching 0.5653 (NS) 1.35 0.49 3.75 
β1‐6 Branching 0.1685 (NS) 2.04 0.74 5.65 
4-linked GlcNAc 0.2910 (NS) 1.68 0.64 4.42 
Outer‐Arm 
Fucosylation 
0.0769 (NS) 2.61 0.90 7.58 
Stage IV 
 
n = 94 
2-linked Mannose 0.0131 (NS) 2.19 1.18 4.05 
α2‐6 Sialylation 0.0051 2.42 1.30 4.50 
β1‐4 Branching 0.0011 2.82 1.51 5.26 
β1‐6 Branching 0.0032 2.53 1.36 4.67 
4-linked GlcNAc 0.0220 (NS) 2.19 1.12 4.31 
Outer‐Arm 
Fucosylation 
0.0081 2.31 1.24 4.31 
aCox proportional hazards regression model p values and hazard ratios for the top quartile for each glycan 
node vs. all other quartiles combined, and lower and upper bound at 95% confident limits of hazard ratios 
are provided.  
b“NS” indicates no statistically significance between hazard ratio and 1, representing no difference in the 
relative risk of death, comparing patients in the top quartile vs. all other quartiles of the respective glycan 
node. The significant levels of p values are adjusted by Bonferroni multiple comparison correction: p > 
0.0083 (NS), p < 0.0083 (*), p < 0.0017 (**), p < 0.00017 (***). 
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CHAPTER 3 
A SPIN COLUMN-FREE APPROACH TO SODIUM HYDROXIDE-BASED 
GLYCAN PERMETHYLATION 
3.1 Introduction 
Glycans are complex carbohydrates that play important roles in numerous 
biological processes, such as intercellular trafficking, signal transduction, cell adhesion, 
endocytosis, immunosurveillance, and immune response initiation160, 161. Recently, 
much attention has been focused on the structural analysis and quantification of glycans 
in order to elucidate their biological roles in chronic human diseases, most notably 
cancer 10, 162, 163. 
Permethylation is a useful derivatization method that confers several advantages 
with regard to the analysis of glycans—especially when combined with mass 
spectrometry (MS). It helps facilitate the determination of sequence and composition 
of monosaccharides in glycans, branching position and interglycosidic linkage 
information, and the presence of configurational and conformational isomers. 
Additionally, permethylation stabilizes sialic acid residues in glycan structures, 
improves measurement sensitivity, enhances separation of glycans by reversed-phase 
HPLC, and generates more predictable spectral patterns when subjected to tandem mass 
spectral (MS) analysis73, 76. Moreover, permethylation helps facilitate quantitative 
reproducibility when glycans are analyzed by matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) MS164. 
The first carbohydrate permethylation methodology was reported by Purdie and 
Irvine in 190378. Since that time, several improved permethylation procedures have 
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been developed. In 1964, Hakomori introduced a procedure with enhanced 
permethylation yield compared to previously described procedures by utilizing sodium 
methylsulfinyl carbanion (Na dimsyl) and iodomethane80. However, even with some 
modifications81-83, the Hakomori procedure was still laborious and hazardous because 
the dimsyl reagent is extremely sensitive to moisture, air and carbon dioxide. In 1984, 
to circumvent these problems with the dimsyl reagent, Ciucanu and Kerek developed a 
procedure based on the reaction of glycans with iodomethane in dimethyl sulfoxide 
(DMSO) containing powdered sodium hydroxide (NaOH)84. This procedure has been 
successfully applied in various glycan structural studies and adopted or adapted by 
numerous laboratories 165. The permethylation yield of this procedure for glycans 
containing N-acetylhexosamine (HexNAc) units, however, was not examined—
perhaps because, as we have found, the yield of HexNAc residues is rather low with 
this procedure (unpublished data).  More recently, a solid-phase spin column-based 
permethylation procedure was pioneered by Mechref, Novotny and coworkers73, 85 for 
the analysis of small quantities of glycans, which could not be satisfactorily achieved 
by the Ciucanu procedure. In this procedure, the reaction of glycans with iodomethane 
is proposed to take place on the surface of NaOH beads that are packed in micro-spin 
columns. Since the solution-phase permethylated glycans are separated from the NaOH 
beads by centrifugation following the reaction, the issues associated with peeling 
reactions and oxidative degradation of glycans due to the presence of NaOH during the 
subsequent liquid/liquid extraction step are avoided. With its high derivatization 
efficiency and good analytical reproducibility, this procedure has demonstrated its 
utility for model glycoproteins and glycans derived from biomedical samples—even 
with low picomole to femtomole sample quantities. N-glycans, however, still need to 
be pre-isolated from glycoproteins and complex biological samples prior to 
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permethylation with the spin column procedure. In 2013, we adapted this 
permethylation method and incorporated trifluoroacetic acid (TFA) hydrolysis, 
reduction, and acetylation steps, to perform glycan linkage analysis directly from whole 
biofluids (such as serum and plasma) and homogenized tissue samples (Fig. 3.1)74, 75. 
With the additional steps, O-linked glycans, N-linked glycans, and glycolipids are all 
released and ultimately converted into partially methylated alditol acetates (PMAAs, 
Fig. 3.2) which are highly amenable to analysis by gas chromatography-mass 
spectrometry (GC-MS). Relative quantification of the resulting PMAAs (as surrogates 
for monosaccharide-and-linkage specific “glycan nodes”) facilitates detection of 
changes in unique glycan features due to disease pathobiology74.  Based on the unique 
branch points and linkages that they represent, some glycan nodes serve as 1:1 
molecular surrogates of corresponding glycosyltransferases—the enzymes that 
facilitate construction of glycan polymers.  Moreover, by analytically pooling together 
each chemically distinct glycan node from across all intact glycans in a complex sample, 
the approach condenses unique glycan structural features such as “core fucosylation”, 
“6-sialylation”, “bisecting GlcNAc”, and “β1-6 branching” into single analytical 
signals (Fig. 3.1). 
Herein we describe and document the performance characteristics of a new 
procedure that eliminates the need for a spin column when permethylating glycans from 
complex biological samples. Glycans containing HexNAc units and small glycan-
containing samples from whole biofluids are readily permethylated by the new 
procedure. Permethylation efficiency is compared to standard spin column-based 
approaches based on both PMAA yield as well as intact permethylated O- and N-glycan 
yields. Finally, we evaluated the reproducibility of the spin column-free procedure 
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toward relative quantification of glycan nodes in blood plasma and assessed its clinical 
performance with regard to its ability to generate glycan nodes that distinguish breast 
cancer patient plasma from that of healthy, aged-matched controls. 
3.2 Materials and Methods 
3.2.1 Materials and samples 
Materials: Galactopyranosyl-β-1,4-N-acetyl-D-glucosamine and 3-O-(2-
Acetamido-2-deoxy-β-D-galactopyranosyl)-D-galactopyranose were obtained from 
Carbosynth (Compton, Berkshire, UK). Peptide-N-Glycosidase F (500 000 units/mL) 
was acquired from New England Biolabs (Ipswich, MA). Fetuin from fetal bovine 
serum and Bovine Ribonuclease B were purchased from Sigma-Aldrich (St. Louis, 
MO). Acetone was purchased from Avantor Performance Materials (Center Valley, 
PA). Methanol was obtained from Honeywell Burdick & Jackson (Muskegon, Ml). 
Acetonitrile and methylene chloride were acquired from Fisher Scientific (Fair Lawn, 
NJ). DMSO, iodomethane (99%, Cat. No. I8507), iodomethane-d3 (99%, Cat. No. 
176036), chloroform, trifluoroacetic acid (TFA), ammonium hydroxide, sodium 
borohydride, acetic anhydride, 2,5-Dihydroxybenzoic acid (DHB), sodium acetate and 
sodium hydroxide beads (20-40 mesh, Cat. No. 367176) were purchased from Sigma-
Aldrich. Pierce spin colunns (900 μL volume) used in the 10 min permethylation 
procedure were obtained from ThermoFisher Scientific (Waltham, MA, Cat.No. 69705). 
Micro-spin columns (500 μL volume) for extended spin column permethylation 
procedure were purchased from Harvard Apparatus (Holliston, MA, Cat. No. 74-4420). 
GC-MS autosampler vials and Teflon-lined pierceable caps were obtained from 
ThermoFisher Scientific. GC consumables were acquired from Agilent (Santa Clara, 
CA); MS consumables were obtained from Waters (Milford, MA). 
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Plasma Samples: A set of 40 blood plasma samples, half from stage III-IV breast 
cancer patients and half from age-matched healthy women, were purchased from 
Bioreclamation IVT (Hicksville, NY). A 300-mL plasma sample from an individual 
donor was also obtained from Bioreclamation, which served as a quality control sample 
to ensure batch-to-batch quantitative reproducibility. 
3.2.2 Experimental Procedures 
3.2.2.1 Permethylation procedures 
Spin column-free (SCF) permethylation procedure: Approximately 625 mg of 
sodium hydroxide (NaOH) beads were collected in a silanized 13 × 100 glass test tube, 
and then conditioned by one rinse with 350 μL of acetonitrile (ACN) followed by two 
rinses with 350 μL of DMSO. Thirty microliters (30 μL) of aqueous sample solution 
and 270 µL of DMSO were added to the preconditioned NaOH beads, followed by the 
addition of 105 µL iodomethane. The solution was then mixed thoroughly on a shaker 
at 650 rpm for 11 min. Next, to dissolve the NaOH beads and create a neutral to slightly 
acidic solution, 3.5 mL of acidified phosphate buffer was slowly added to each sample 
with continual mixing by manual swirling. To make the acidified buffer, concentrated 
hydrochloric acid (HCl) was mixed with 0.2 M phosphate buffer (composed of half 0.2 
M Na2HPO4 and half 0.2 M NaH2PO4, pH 7) at a 1.3 : 2.2 volume ratio. Then 1.2 mL 
of chloroform was added and mixed thoroughly with the aqueous layer. After brief 
centrifugation (30s at 3000 g), the top layer (aqueous layer) of each sample was 
discarded, and replaced by a fresh 3.5-mL aliquot of 0.5 M NaCl solution in a 0.2 M 
sodium phosphate buffer (pH 7). Two additional liquid/liquid extraction cycles with 0.2 
M sodium phosphate buffer (pH 7) were then performed. At last, the chloroform layer 
of each sample was collected and then dried under vacuum (Speed Vac) with no heat 
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applied (for further intact glycan analysis) or under a gentle stream of nitrogen (if the 
sample was to undergo glycan linkage analysis). 
10 min spin column (SC 10 min) permethylation procedure: The following 
procedure was employed by Borges et al. in 201374 and 201675. Sodium hydroxide 
beads were collected in a Pierce spin column (900 µL volume) up to 5 mm below the 
brim, and washed once with 350 µL of acetonitrile (ACN) followed by two rinses with 
350 µL of DMSO. Nine microliters (9 µL) of aqueous glycan standard solution or a 
whole biofluid sample (e.g., blood plasma, serum, homogenized tissue, etc.) were 
mixed with 270 µL of DMSO in a 1.5 mL Eppendorf tube. The solution was added to 
the pre-conditioned NaOH beads in the plugged microfuge spin column, followed by 
the addition of 105 µL of iodomethane and immediate stirring. The sample mixture was 
then allowed to stand for 11 min with occasional gentle stirring. After reaction, the 
microfuge spin column was unplugged and spun for 30 s at 5000 rpm (1000 g in a fixed-
angle rotor) to collect the sample solution, which was quickly transferred into 3.5 mL 
of 0.5 M NaCl solution in 0.2 M sodium phosphate buffer (pH 7) within a silanized 13 
× 100 glass test tube. NaOH beads were then washed twice by 300 µL of ACN, and the 
spin-throughs were all immediately transferred into the same silanized glass test tube. 
To each sample, 1.2 mL of chloroform was added to perform liquid/liquid extraction. 
With brief centrifugation (as above), the top layer (aqueous layer) was discarded and 
then replaced by a fresh aliquot of 3.5 mL of 0.5 M NaCl solution in 0.2 M sodium 
phosphate buffer (pH 7). In total, three L/L extractions were performed for each sample, 
and finally the chloroform layer was extracted and then dried under vacuum (Speed 
Vac) with no heat applied (for further intact glycan analysis) or under a gentle stream 
of nitrogen (if the sample was to undergo glycan linkage analysis). 
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Extended spin column (SC 50 min) permethylation procedure: The following 
procedure was adapted from the protocol of Mechref et al.166 Sodium hydroxide beads 
were added to a Harvard Apparatus micro-spin column (500 µL volume) up to 3 cm in 
height and washed twice with 50 µL of DMSO. In a 0.5 mL Eppendorf tube, 1.2 µL of 
aqueous glycan standard solution was mixed with 30 µL of DMSO. After mixing with 
20 µL of iodomethane, the sample mixture was applied to the sodium hydroxide beads 
packed in a spin column. The sample mixture was allowed to stand for 30 min, followed 
by the addition of another 20 µL of iodomethane and 20 min incubation. The sample 
was collected by centrifugation at 200 g for 1 min after reaction, and the NaOH beads 
were washed twice by 50 µL of DMSO. The sample and two eluted volumes of DMSO 
were collected in a silanized 13 × 100 glass test tube. To perform L/L extractions, 3.5 
mL of 0.5 M NaCl solution in 0.2 M sodium phosphate buffer (pH 7) and 1.2 mL 
chloroform were added to each sample. The chloroform layer was washed 3 times with 
the aqueous solution, then extracted and dried under vacuum (Speed Vac) with no heat 
applied (for further intact glycan analysis) or under a gentle stream of nitrogen (if the 
sample was to undergo glycan linkage analysis). 
As carried out here, the final L/L extraction steps were necessary in order to 
facilitate subsequent analysis by GC-MS or MALDI-MS.  As recently described 
elsewhere 167, 168, however, the effluent from the extended spin column procedure can 
simply be dried and reconstituted in LC-MS mobile phase provided that online 
desalting is carried out on the LC prior to elution of the permethylated glycans into the 
mass spectrometer. LC-MS was not employed in the studies described here, but it is 
unlikely that the product of the SCF procedure described above would be amenable to 
this L/L extraction-free, dry, dilute and shoot approach due to the high concentration of 
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salts that are present following dissolution of the NaOH beads with acidified phosphate 
buffer. 
3.2.2.2 Glycan linkage analysis 
Permethylation: Permethylation was carried out following one of the procedures 
listed above. 
Hydrolysis, reduction, and acetylation: Hydrolysis, reduction and acetylation 
were carried out as we have previously described74, 75. Two molar TFA was prepared 
and added (325 µL) to each test tube and allowed to react for 2 h at 120 °C. Samples 
were dried under a gentle stream of nitrogen at 73 °C. Next, 10 mg/mL sodium 
borohydride in 1 M ammonium hydroxide was freshly prepared and added (475 µL) to 
each sample, which was allowed to stand for 1 h in room temperature. To remove excess 
borate, 100 µL of methanol (MeOH) was added and dried under nitrogen, followed by 
125 µL of 9:1 (v/v) MeOH : acetic acid and drying under nitrogen. To achieve efficient 
acetylation, 18 µL of deionized water was added to each test tube, thoroughly mixed 
and sonicated for 2 min to dissolve any precipitates. Then each sample was mixed with 
250 µL acetic anhydride and heated at 50 °C for 10 min, followed by adding 230 µL of 
concentrated TFA and heating again at 50 °C for 10 min. To clean up the sample 
mixture, 1.8 mL of dichloromethane and 2 mL of deionized water were added to 
perform liquid/liquid extraction twice, with the aqueous layer discarded for each cycle. 
The organic layer of each sample was transferred to a silanized autosampler vial, and 
then dried under a gentle stream of nitrogen at 40 °C. 
Gas chromatography-mass spectrometry: An Agilent Model A7890 gas 
chromatograph (equipped with a CTC PAL autosampler) coupled to a Waters GCT 
(time-of-flight) mass spectrometer was employed for analysis of PMAAs by GC-MS. 
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To each sample vial, 64 µL of acetone was added to reconstitute the PMAAs. One 
microliter (1 µL) was then injected onto a hot (280 °C), silanized glass liner containing 
a plug of silanized glass wool (Agilent Cat. No. 5183-4647) at split ratio of 20. Samples 
were separated via chromatography over a 30 m DB-5ms GC column, facilitated by 
helium as carrier gas with a 0.8 mL/min constant flow rate. The GC oven was held at 
an initial temperature of 165 °C for 0.5 min, ramped to 265 °C at a rate of 10 °C/min, 
followed by immediately ramping to 325 °C at a rate of 30 °C/min and holding at 325 °C 
for 3 min. Sample components eluted from GC column into the TOF mass spectrometer 
equipped with an electron ionization source (70 eV, 250 °C). MS spectra were collected 
in positive-ion mode. Spectra from individual TOF pulses over a m/z range of 40-800 
were summed every 0.1s. The mass spectrometer was tuned and calibrated daily using 
perfluorotributylamine to ensure reproducible relative abundances of EI ions and mass 
accuracy within 10 ppm. 
3.2.2.3 Intact glycan analysis 
Enzymatic release and reduction of N-glycans: The following procedure, 
including the amount of glycoprotein employed, was adapted from Hu et al. for release 
and reduction of N-glycans166. A 10 mg/mL stock solution of N-glycoprotein (Bovine 
Ribonuclease B) was prepared. A 1 µL aliquot of the stock solution was mixed with 9 
µL GlycoBuffer 2 (10×, 50mM sodium phosphate buffer, pH 7.5). Next, the mixture 
was heated in boiling water for 10 min, and then chilled on ice. Peptide-N-Glycosidase 
F (PNGase F) stock solution (500,000 units/mL) was diluted ten times with 
GlycoBuffer 2, and added (1 µL) to each sample. The glycoprotein samples were then 
incubated at 37 °C for 18 h, and dried under vacuum with assisted heat at approximately 
55 °C.  
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A 10 mg/mL solution of sodium borohydride in 1 M ammonium hydroxide 
solution was freshly prepared and added (10 µL) to each sample, which was then 
incubated in a 60 °C water bath for 1 h. Samples were mixed with 10 µL of 5% acetic 
acid, and dried under vacuum with assisted heat. Next, HPLC-grade methanol was 
added (100 µL) to each sample and removed by drying under vacuum. To eliminate 
residual borate in samples, the last two steps were repeated five times. 
Permethylation: Permethylation was carried out following one of the procedures 
listed above. 
MALDI-TOF mass spectrometry: The dried permethylated samples were 
reconstituted in 6 µL of ethanol. A 10 mg/mL 2,5-Dihydroxybenzoic acid (DHB) 
matrix solution was made in 1 mM sodium acetate solution. To directly compare 
samples derivatized with the SCF vs. SC 50 min procedures, 1 µL of sample 
permethylated by the SC 50 min procedure with iodomethane and 1 µL of sample 
permethylated by the SCF procedure with iodomethane-d3 were mixed into 2 µL of 
DHB matrix solution, making a solution with a total volume of 4 µL. Next, 2 µL of the 
mixed solution was transferred onto a MALDI target spot, and then dried under vacuum 
for 10 min. 
A Bruker Daltonics, Autoflex Ⅲ L200 MALDI-TOF mass spectrometer was 
utilized for intact glycan analysis. The instrument was used in linear, positive ion, 
delayed-extraction mode, with ‘ionsource 1’ at 20 kV, ‘ionsource 2’ at 18.45 kV, lens 
at 7.7 kV, 50 ns delayed extraction, deflection signal suppression up to m/z 500, and 1 
GS/s sample rate. To ensure good ion counting statistics, at least 2500 laser-shots were 
signal averaged for each mass spectrum. The MALDI-TOF mass spectrometer was 
externally calibrated with peptide calibration standard II, a mixture of 9 peptides 
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supplied by Bruker Daltonics (Cat. No. NC9349683). 
3.2.3 Data analysis 
GC-MS data: Masslynx 4.1 program and Quanlynx 4.1 software were utilized 
to process all GC-MS data for glycan linkage analysis. For routine relative 
quantification of each glycan “node” from glycan standards or blood plasma, the 2-4 
most abundant and/or diagnostic fragment ions74, 75 were summed using a 0.15 Da 
extracted ion chromatogram mass window for quantification. The summed extracted 
ion chromatogram (XIC) peak areas were automatically integrated and quantified, then 
exported to a spreadsheet for further calculation. All integration events were evaluated 
manually to ensure accuracy. 
Permethylation efficiency was determined by the fraction of ion signal derived 
from PMAAs representing undermethylated form(s) of a specific glycan node divided 
by this same value plus the ion signal derived from the PMAA representing the fully 
permethylated form of that particular glycan node. (For example, for analysis of the 
Gal-4-GlcNAc standard, ion signal from the PMAA representing terminal galactose (t-
Gal) represented the fully permethylated hexose while all other galactose-related ion 
signals such as those from PMAAs representing 2-Gal, 3-Gal, 4-Gal, etc. represented 
undermethylated forms of the t-Gal residue.) Because the total ion current 
chromatogram (TIC) contained a few chromatographic signals from sample 
preparation-related non-glycan contaminants that, in some cases, co-eluted with 
PMAAs of interest, extracted ion chromatograms had to be employed for this analysis.  
As such, we ensured that ions extracted for analysis of glycan undermethylation (see 
Table 3.1 and 3.2) covered greater than 90% of the ion current derived from the 
corresponding glycan node. 
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MALDI-TOF MS data: MALDI MS data for intact glycan analysis were 
processed by Bruker FlexAnalysis 3.0 software. Mass spectra were baseline subtracted 
using the TopHat algorithm, and MS peaks were integrated baseline-to-baseline. 
Integration events were inspected manually and, if necessary, adjusted to baseline as 
appropriate. Peak intensities were exported to a spreadsheet for further calculation. 
Calculated masses of the permethylated O-glycans from fetuin and N-glycans from 
ribonuclease B are provided in Table 3.3 and 3.4. 
To directly compare the permethylation efficiency of the spin column-free 
procedure (SCF) and extended spin column procedure (SC 50 min), the intensity ratio 
of mass spectral peaks from the two procedures (SCF/SC 50 min) was calculated for 
each intact glycan. Every experiment was also run with the labeling reagents switched 
(i.e., iodomethane used for the SCF procedure and iodomethane-d3 used for the SC 50 
min procedure), then all results were pooled together to ensure a lack of labeling bias. 
Statistical Analysis Software: Software employed for statistical analysis 
included Microsoft Excel for the two-tailed Student’s t-test to compare the 
experimentally determined mean SCF/SC ratio for each glycoform with the theoretical 
value of 1. Excel was also used for the Benjamini-Hochberg false discovery rate 
adjustment of p-values for the Wilcoxon rank sum test. GraphPad Prism 5 was utilized 
for Kruskal-Wallis followed by Dunn’s posthoc tests. And SAS 9.4 was employed for 
the Wilcoxon rank sum test.  
3.3 Results and Discussion 
3.3.1 Optimization of permethylation reagent volumes and order of addition for 
the spin column-free (SCF) permethylation procedure 
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To maximize permethylation efficiency of the SCF procedure, several 
parameters were assessed, including total volume of water in the original sample and 
order of reagent addition. Holding the volume of DMSO and iodomethane constant, the 
effect of sample water volume on permethylation yield was investigated at total water 
volumes of 10 μL, 20 μL, 30 μL, 40 μL and 80 μL. These volumes are given assuming 
that the original sample is aqueous in nature and constitutes a fraction of the stated 
volumes. N-acetylactosamine (LacNAc), composed of terminal galactose (t-Gal) linked 
to the 4-position of N-acetylglucosamine (4-GlcNAc), was chosen as the glycan 
standard for the assessment of permethylation efficiency, since the permethylation 
yields of both hexose and N-acethylhexosamine (HexNAc) monomer units can be 
evaluated from it simultaneously. For each sample, 5 µg of LacNAc was dissolved into 
the volumes of water listed above, and then processed by spin column-free 
permethylation followed by hydrolysis, reduction and acetylation steps. 
As shown in Fig. 3.3, the highest permethylation efficiencies for both the hexose 
and HexNAc units, were found in samples with total original-sample water volumes of 
more than 30 μL. For samples with 30 μL total volume, less than 2% of hexose and less 
than 1% of HexNAc were undermethylated. But for samples with total original-sample 
water volumes under 30 μL, the permethylation efficiencies were not as good, 
evidenced by higher mean values and significantly higher undermethylation fractions 
(especially for 10 μL) based on Kruskal-Wallis followed by Dunn’s posthoc tests. 
Based on previous work published by Ciucanu and coworkers77, a small amount of 
water added to the permethylation system improves the solubility of glycans in organic 
solvents, such as DMSO, which is critical for the permethylation reaction. However, 
too much water added to the sample can lead to undesired effects on the permethylation 
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efficiency, due to the oxidative degradation of glycans in basic solution. In accordance 
with the previous work by Ciucanu et al.77, a paste of sodium hydroxide was found on 
the walls of the test tubes immediately following the 11-minute incubation with NaOH 
beads for samples with a total volume above 40 μL, which could potentially result in 
inconsistent permethylation yields. Therefore, 30 μL was selected as the optimal 
original-sample water volume and was used in subsequent experiments. 
The order in which water/DMSO-solubilized glycan samples were exposed to 
either iodomethane or the NaOH beads was also evaluated with regard to its impact on 
permethylated glycan yield. Generally, iodomethane was added to samples before the 
NaOH beads, even though sometimes a color change appeared suggesting oxidative 
degradation of glycans might be taking place77. To evaluate the possibility of 
completely avoiding oxidative degradation, samples were added to NaOH beads first, 
followed by addition of iodomethane. Five micrograms (5 µg) of LacNAc were 
permethylated by the SCF permethylation procedure, followed by hydrolysis, reduction 
and acetylation (n = 6 each). To compare the degrees of oxidative degradation for the 
two orders of reagent addition, the total ion signals (raw summed peak areas of XICs 
representing > 90% of the total ion PMAA ion signal) of t-Gal and 4-GlcNAc, as well 
as the ratios of 4-GlcNAc to t-Gal were tested by Wilcoxon rank sum test. No 
statistically significant differences were found for the degree of oxidative degradation 
of hexose and HexNAc units between the two orders of reagent addition (p = 0.7922 
for t-Gal, and p = 0.6623 for 4-GlcNAc); neither was the HexNAc/hexose ratio 
significantly different. Even so, to minimize the risk of oxidative degradation it is 
preferable to add water/DMSO-solubilized samples to NaOH beads first followed by 
iodomethane.  
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3.3.2 Permethylation efficiency of the SCF procedure relative to spin column-
based approaches 
To validate the permethylation efficiency of our spin column-free procedure, 
we compared it with two other published and prevalent spin column-based 
permethylation procedures. One spin column permethylation procedure with 10 min 
reaction time (SC 10 min) was developed by Kang et al73, Goetz et al169 and further 
modified by Borges et al75, the details of which can be found in their recently published 
work. A second spin column permethylation procedure with 50 min reaction time (SC 
50 min) was summarized in recent work of Hu et al.166 2-Acetamido-2-deoxy-D-lactose 
(Gal-4GlcNc, a.k.a. LacNAc) and 3-O-(2-Acetamido-2-deoxy-β-D-galactopyranosyl)-
D-galactopyranose (GalNAc-3Gal) were chosen as the model glycan standards for the 
investigation, both of which are disaccharides composed of hexose and HexNAc 
residues but with switched positions (reducing or non-reducing end) of the two classes 
of monosaccharides. We processed 5-µg samples of glycan standard with the three 
different permethylation procedures in parallel, then performed the hydrolysis, 
reduction and acetylation procedures together (i.e., with all samples in the same batch) 
to reduce variability in steps other than permethylation. 
The undermethylated fraction of each monosaccharide was calculated (refer 
back to Method section) and results were evaluated by Kruskal-Wallis followed by 
Dunn’s posthoc tests (Fig. 3.4). The data revealed that the spin column-free procedure 
has comparable or slightly better permethylation efficiency for hexoses and HexNAcs 
in comparison with the two spin column procedures (Fig. 3.4). According to our 
previous work75, HexNAc residues are more susceptible to pH change in the aqueous 
solution before liquid/liquid extraction and thus have a higher risk of undergoing 
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oxidative degradation during permethylation than hexoses. But as shown here (Fig. 3.4), 
the undermethylation of HexNAc residues by the spin column-free procedure can reach 
as low as 1.4% (for 4-GlcNAc) and 0.4% (for t-GalNAc), demonstrating optimal 
control of permethylation efficiency by the spin column-free procedure. The peak areas 
under the summed extracted ion chromatograms (XICs) of hexose and HexNAc 
residues (refer to Method section and Table 3.1 and 3.2) were compared by evaluating 
their ratios, as shown in Fig. 3.4e and 4f. Even with apparently lower relative yields of 
HexNAc residues for SCF procedure compared to the other two spin column procedures, 
the HexNAc/hexose ratios for the SCF procedure were sufficiently consistent and 
reproducible, which is critical during the routine analysis of biological samples. 
3.3.3 Analysis of intact glycans following SCF permethylation 
Generally, permethylation is utilized by most researchers to facilitate analysis 
of intact glycans. The spin column-free permethylation procedure can also be applied 
to intact O-glycan analysis, as well as intact N-glycan analysis if coupled with the 
release of glycans from N-glycoproteins. Therefore, we characterized the efficiency of 
SCF vs. spin column permethylation procedures for both intact O- and N-linked glycans. 
Fetuins are heavily glycosylated proteins that carry both O- and N-linked 
glycans. Within the permethylation step, O-glycans are cleaved from the protein by β-
elimination, while N-glycans remain attached169. Three samples of 145 µg of Fetuin 
were processed by the extended spin column permethylation procedure (SC 50 min), a 
commonly used spin column-based procedure166, 170-174. In parallel, 3 samples were 
processed with the SCF procedure but were permethylated with iodomethane-d3. 
Samples treated by the two procedures were re-consitituted in 6 μL ethanol, mixed at a 
1:1 ratio in a DHB matrix solution, and 2 μL was spotted onto a MALDI target. All 
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three samples derivatized by the SCF procedure with iodomethane-d3 were mixed in all 
possible combinations with the three samples processed by the SC 50 min procedure 
that employed unlabeled iodomethane, leading to a total of 9 combinations (3 × 3). To 
eliminate the possibility of labeling reagent bias, the two procedures were carried out 
again on the same samples but with the labeling reagents switched. 
The SCF procedure effectively permethylated all three major types of O-glycans 
from Fetuin-A (Fig. 3.5), with O-linked tetrasaccharides (NeuAc2-Hex-HexNAc) and 
hexasaccharides (NeuAc2-Hex2-HexNAc2) permethylated at nearly the same efficiency 
as the more commonly employed spin column-based procedure 166. Highly averaged 
MALDI-MS peak intensities of identical glycoforms processed with the two procedures 
were compared directly and are shown as the SCF/SC ratio in Fig. 3.6. An SCF/SC 
ratio of 1 would indicate identical permethylation efficiency and yield for the two 
procedures. As such, we used a two-tailed Student’s t-test to compare the 
experimentally determined mean SCF/SC ratio for each glycoform with the theoretical 
ratio of 1 (which would indicate an equal yield from the two procedures), using equation 
1175. 
𝑡 =  ௫̅ିఓ
௦/√ே
                             (Eq. 1)  
 where t is the t-statistic, ?̅? is the sample mean, 𝜇 is the theoretical population 
mean of 1, s is the sample standard deviation, and N is the number of observations.  For 
the case of tetra- and hexasaccharides, the SCF/SC ratios were nearly 1, despite the fact 
that the t-statistic for the tetra-saccharide was slightly higher than the critical value of t 
(tcrit) at the 99% confidence level (CL). Relative to the SC procedure, the SCF procedure 
was found to result in significantly lower yields of O-linked trisaccharides (NeuAc-
Hex-HexNAc), mean SCF/SC ratio = 0.50) (Fig. 3.6). The mechanism underlying this 
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phenomenon is not known, but it is not likely caused by less efficient permethylation 
in the SCF procedure (cf. Fig. 3.4). It could, however, be related to relatively higher 
solubility of the permethylated trisaccharide in the aqueous layers of SCF samples, 
which have a lower pH during extraction—potentially resulting in decreased extraction 
efficiency. For larger O-linked glycans (tetra- and hexasaccharides), the comparison 
demonstrated that the SCF procedure produces nearly the same permethylated glycan 
yield as the widely employed spin column procedure (SC 50 min)166. 
To investigate the effectiveness of the SCF procedure on permethylation of N-
glycans in comparison with the spin column procedure, 10 µg of bovine ribonuclease 
B (RNase B), a well-known N-glycoprotein with only one N-glycosylation site, which 
bears one of four major high-mannose N-glycans was employed176 (Fig. 3.5). Since 
only O-glycans are released from proteins by β-elimination during the permethylation 
step169, traditional enzymatic cleavage steps were adopted to release N-glycans from 
the glycoprotein (see Methods section). Using the comparison strategy described above 
for O-glycans, the SCF/SC ratios for the four major RNase B N-glycans were compared 
to the theoretical value of 1 by a two-tailed Student’s t-test. Calculated t-statistics were 
larger than tcrit at the 99% CL, indicating that the SCF procedure produces a higher yield 
of permethylated high-mannose N-glycans compared to a widely used-spin column 
procedure (SC 50 min) (Fig. 3.6). Notably, while low-microgram quantities of RNase 
B were required to facilitate consistently high signal-to-noise (S/N) levels for this 
quantitative comparison, the SCF-based analysis was also run with 100 ng of RNAse 
B to demonstrate the sensitivity of the new approach. The S/N ratio for all four glycans 
was greater than 5 (results not shown).  
3.3.4 Application of the SCF procedure to human blood plasma 
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As shown by Borges et al in 201374, spin-column based permethylation of whole 
biofluids and homogenized tissues followed by hydrolysis, reduction and acetylation 
can be used to generate composite glycan linkage analysis data from all major classes 
of glycans—including not only O-linked glycans, but N-linked and lipid-linked glycans 
as well—without the need for glycan-releasing enzymes. Relative quantification of 
each hexose is carried out by dividing its summed XIC peak area by the sum of all 
hexose XIC peak areas; likewise, relative quantification of each HexNAc is carried out 
by dividing its summed XIC peak area by the sum of all HexNAc XIC peak areas. These 
normalized abundances (NAs) are then used for further evaluation of biological 
differences between samples from donors with and without disease75.  To determine the 
reproducibility of the SCF permethylation procedure as applied to blood plasma, 9-μL 
aliquots of an EDTA blood plasma sample from an individual donor were processed by 
SCF permethylation followed by hydrolysis, reduction, acetylation and analysis by GC-
MS as we have previously described74. Six 9-μL aliquots were processed and analyzed 
three different times (i.e., 18 samples total in three separate batches) to evaluate intra- 
and interassay reproducibility. Shown in Table 3.5 are the intra- and inter-assay 
reproducibility of all glycan nodes for which the mean normalized abundances 
contribute more than 1% of the total hexose or HexNAc signal. Average intra-assay 
reproducibility was 9.7% and inter-assay reproducibility was 17.7%. Of these 16 
routinely detected glycan nodes in plasma samples, 15 had intra- and inter-assay 
reproducibility of less than 20% for SCF procedure. These metrics of analytical 
precision are comparable to those of the 10-min spin column permethylation procedure, 
as reported by Borges et al in 2016 75. The quantitatively inconsistent glycan node, 4-
Glc, typically constitutes about 5% of the total hexose signal, but is a node that is 
primarily derived from glycolipids—which may behave differently than N- and O-
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linked glycans under the sample processing conditions applied. 
3.3.5 Application of the SCF permethylation procedure to glycan node analysis of 
blood plasma from breast cancer patients 
The new SCF permethylation procedure was coupled to hydrolysis, reduction 
and acetylation and applied to a cohort of 40 blood plasma samples from breast cancer 
patients (stages III-IV, n = 20) and age-matched female controls (n = 20). Samples were 
randomized and analyzed blindly in seven batches as we have previously described75. 
Three glycan nodes with between-batch reproducibility of 16 %CV or better (Table 3.5) 
were found to be significantly different in the late stage-breast cancer samples 
compared to controls, according to a Wilcoxon rank sum test and Benjamini-Hochberg 
false discovery rate adjustment procedure with p-values less than 0.05 (shown in Fig. 
3.7). The receiver operating characteristic (ROC) c-statistics (AUCs) of the three glycan 
nodes were in the range of 0.75-0.85 (Fig. 3.7), demonstrating that 2,4-linked mannose 
(2,4-Man), 2,6-linked mannose (2,6-Man) and 4,6-linked GlcNAc (4,6-GlcNAc) may 
potentially be useful as markers for stage III-IV breast cancer. Interestingly, these three 
glycan nodes represent the sum total of β1-4 branching, β1-6 branching, and core 
fucosylation, respectively—as pooled together from all intact glycans within each 
sample. 
3.4 Conclusions 
A new spin column-free (SCF) permethylation procedure that reduces 
consumable costs and the number of experimental steps required for glycan 
permethylation was developed and applied to mass spectrometry-based intact-glycan 
analysis and linkage-analysis of glycans from whole biospecimens. The permethylation 
efficiency of the new SCF procedure reached as high as 98% for hexose residues and 
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99% for HexNAc residues, which are values comparable to or slightly higher than those 
of some widely-used spin column-based procedures. With regard to intact glycan 
analysis, the SCF procedure provided almost identical yields for permethylated O-
glycans composed of more than three monosaccharides, and higher yields for the 
permethylated N-glycans examined. The SCF permethylation approach, combined with 
hydrolysis, reduction and acetylation facilitated glycan linkage analysis of pooled 
glycans from unfractionated blood plasma with good quantitative reproducibility. 
Furthermore, glycan linkage analysis with the SCF procedure identified specific, 
previously unreported glycan “nodes” representative of β1-4 branching, β1-6 branching, 
and core fucosylation as potential markers of stage III-IV breast cancer. 
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Figures 
 
Figure 3.1: Conceptual overview of glycan linkage analysis from whole biospecimens. 
Intact normal and abnormal glycans including O-glycans, N-glycans and glycolipids, 
are processed and transformed into partially methylated alditol acetates (PMAAs, Fig. 
3.2), each of which corresponds to a particular monosaccharide-and-linkage-specific 
glycan “node” in the original polymer. As illustrated, analytically pooling together the 
glycan nodes from amongst all the aberrant intact glycan structures provides a more 
direct surrogate measurement of abnormal glycosyltransferase activity than any 
individual intact glycan, while simultaneously converting unique glycan features such 
as “core fucosylation”, “6-sialylation”, “bisecting GlcNAc”, and “β1-6 branching” into 
single analytical signals. Actual extracted ion chromatograms from 9-µL blood plasma 
samples are shown. Numbers adjacent to monosaccharide residues in glycan structures 
indicate the position at which the higher residue is linked to the lower residue. Figure 
adapted with permission from Borges CR et al. Anal. Chem. 2013, 85(5):2927-2936. 
Copyright 2013 American Chemical Society. 
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Figure 3.2: Molecular overview of the glycan linkage analysis procedure. The Gal-4-GlcNAc 
disaccharide is illustrated. For glycans from blood plasma and other biofluids, O-linked glycans 
are released during permethylation, while N-linked glycans and glycolipids are released during 
acid hydrolysis. The unique pattern of methylation and acetylation in the final partially 
methylated alditol acetates (PMAAs) corresponds to the unique “glycan node” in the original 
intact polymer and provides the molecular basis for separation and quantification by GC-MS. 
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Figure 3.3: Effect of original-aqueous-sample volume on permethylation efficiency: 
(a) univariate distribution of the undermethylated fraction of t-Gal, (b) univariate 
distribution of the undermethylated fraction of 4-GlcNAc. N = 6 to 15 for each volume. 
Undermethylated fractions were determined as described in the Methods section. 
Kruskal-Wallis followed by Dunn’s posthoc tests demonstrated significant differences 
in the degree of undermethylation at the tested volumes of water in the original samples. 
Error bars indicate mean ± standard error of the mean (SEM). Single asterisk (*) 
indicates significant differences between groups with p ≤ 0.05. Three asterisks (***) 
indicate significant differences between groups with p ≤ 0.001.  
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Figure 3.4: Evidence that the new spin column-free procedure has comparable permethylation 
efficiency for terminal/non-terminal hexose and terminal/non-terminal HexNAc relative to 
other prevalently used spin column procedures74, 75, 166. Undermethylated fractions were 
calculated and shown for (a) t-Gal from Galactopyranosyl-b-1,4-N-acetyl-D-glucosamine (Gal-
4-GlcNAc), (b) 4-GlcNAc from Gal-4-GlcNAc, (c) 3-Gal from 3-O-(2-Acetamido-2-deoxy-b-
D-galactopyranosyl)-D-galactopyranose (GalNAc-3Gal), and (d) t-GalNAc from GalNAc-
3Gal. Peak areas under summed extracted ion chromatograms (XICs) of the HexNAc species 
were compared with that of hexose species, for both glycan standards, and the ratios were 
shown in (e) 4-GlcNAc/t-Gal, and (f) t-GalNAc/3-Gal. N = 12 for each permethylation 
procedure. Kruskal-Wallis followed by Dunn’s posthoc tests demonstrated significant 
differences in the permethylation procedures. The SCF procedure produces a slightly higher 
undermethylated fraction than the extended SC procedure (SC 50 min) for t-Gal (a), but similar 
or lower undermethylated fractions than the two SC procedures for 4-GlcNAc (b), 3-Gal (c) 
and t-GalNAc (d). Error bars indicate mean ± standard error of the mean (SEM). Single asterisk 
(*) indicates significant differences between groups with p ≤ 0.05. Two asterisks (**) indicate 
significant differences between groups with p ≤ 0.01. Three asterisks (***) indicate significant 
differences between groups with p ≤ 0.001. 
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Figure 3.5: Permethylation of intact glycans by the spin column-free procedure (SCF) 
and extended spin column procedure (SC 50 min)166. a) O-glycans of fetuin from fetal 
bovine serum; b) N-glycans of bovine ribonuclease B. Glycan structure symbols 
indicate the most likely (isomerically ambiguous) corresponding glycan permethylated 
by the SC 50 min procedure with unlabelled iodomethane, or by the SCF procedure 
with iodomethane-d3 (as indicated by “-dn” labels where the subscripts represent the 
number of hydrogen atoms replaced by deuterium atoms in each glycan structure). Red 
lines under the peaks representing permethylated glycans indicate integration baselines.  
Calculated masses of the permethylated glycans depicted are provided in Table 3.3 and 
3.4. 
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Figure 3.6: Ratio of intact, permethylated glycan yields produced by the SCF 
procedure relative to a commonly employed SC procedure (SC 50 min) 166: (a) O-
glycans from Fetuin and (b) N-glycans from bovine ribonuclease B. For each 
glycoform, the highly-averaged intensities of the two MALDI-MS peaks 
corresponding to the two permethylation procedures conducted with light and heavy 
labeling reagents were compared and presented here as the SCF/SC ratio. Two-tailed 
student’s t-test comparing the SCF/SC ratios to the theoretical value of 1 
demonstrated significant differences between the two procedures as indicated (p < 
0.05). Error bars indicate mean ± standard error of the mean (SEM). † indicates 
significant differences between a group mean and the theoretical value of 1. 
  
89 
 
Figure 3.7: Application of the SCF procedure to glycan node analysis 74, 75 of clinical 
samples. Data shown were from blood plasma acquired from 20 stage III-IV breast 
cancer patients and 20 age-matched healthy women. Receiver operating characteristic 
(ROC) analysis of 20 glycan nodes indicated that three glycan nodes have the potential 
to distinguish breast cancer patients from controls: (a) univariate distribution of 2,4-
Man, (b) ROC curve for 2,4-Man, (c) univariate distribution of 2,6-Man, (d) ROC curve 
for 2,6-Man, (e) univariate distribution of 4,6-GlcNAc, and (f) ROC curve for 4,6-
GlcNAc. Data are based on normalized abundance (NA), which is defined as the 
summed XIC peak area of each glycan node divided by the sum of all other hexose (or 
HexNAc) summed XIC areas. For all three glycan nodes, p < 0.01 and AUC (area under 
curve) > 0.75 for ROC curves. Error bars indicate mean ± standard error of the mean 
(SEM). 
  
90 
Tables 
Table 3.1. Extracted Ions for Disaccharide Gal-4-GlcNAc (± 0.15 Da). 
Glycan Nodes Extracted Ions (m/z) 
t-Gal 59.05+71.05+87.04+101.06+117.05+129.05+145.08+161.07+173.08+205.10 
4-Gal 59.05+71.08+87.04+101.06+113.06+117.05+129.05+131.07+161.07+173.07+23
3.11 
2-Gal 59.05+71.05+87.04+101.06+113.05+117.05+129.05+145.08+161.08+189.07+20
5.10 
3-Gal 59.05+74.04+87.06+101.06+117.05+129.05+143.08+161.08+173.07+201.08+23
3.11 
6-Gal 59.05+71.08+87.04+99.04+101.06+117.05+129.05+159.06+161.08+173.07+189
.07+233.11 
3,4-Gal 59.05+74.04+87.04+117.05+129.05+143.08+161.08 
2,3-Gal 86.07+129.05+143.08+161.08+201.08+261.10 
3,6-Gal 98.07+101.06+117.05+129.05+189.07 
4-GlcNAc 74.06+98.06+116.04+142.08+158.08+233.11 
3,4-GlcNAc 74.06+98.06+116.07+142.08+158.08 
4,6-GlcNAc 74.06+98.07+116.07+142.08+158.08 
 
 
Table 3.2. Extracted Ions for Disaccharide GalNAc-3-Gal (± 0.15 Da)a.  
Glycan Nodes Extracted Ions (m/z) 
3-Gal f 59.05+74.04+87.05+101.06+117.06+161.09+171.07+189.09 
3-Gal p 59.05+74.04+87.05+99.05+101.06+117.06+129.06+143.08+161.09+173.09+201
.08+233.11 
3,4-Gal 87.05+99.05+101.06+117.06+129.06+143.07+161.09 
2,3-Gal 86.07+129.06+143.08+161.08+201.08+261.11 
3,6-Gal 98.05+101.05+117.06+129.06+189.06 
t-GalNAc 74.06+87.05+98.06+101.06+116.08+129.06+145.09+158.09+205.12 
3-GalNAc 99.09+116.08+129.05+158.09+171.09+197.09 
4-GalNAc 98.07+116.08+129.05+158.09+233.11 
6-GalNAc 74.06+98.07+116.08+129.05+158.09+189.09+203.1 
3,6-GalNAc 74.06+98.07+116.08+129.05+158.09+171.09+189.09 
aBoth furanose and pyranose form of 3-Gal (3-Gal f and 3-Gal p) were measured and 
summed to obtain a total signal for 3-Gal. 
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Table 3.3. Masses (as [M+Na]+avg) of Intact O-glycans from Fetuin.  
Labeling Reagent Trisaccharide Tetrasaccharide Hexsaccharide 
Iodomethane C38H68N2O19 C54H95N3O27 C74H130N4O37 
[M+Na]+: 879.94 [M+Na]+: 1241.33 [M+Na]+: 1690.82 
Iodomethane-d3 C38H29D39N2O19 C54H41D54N3O27 C74H58D72N4O37 
[M+Na]+: 919.18 [M+Na]+: 1295.66 [M+Na]+: 1763.26 
 
 
Table 3.4. Masses (as [M+Na]+avg) of Intact N-glycans from Ribonuclease B. 
Labeling 
Reagent Man5GlcNAc2 Man6GlcNAc2 Man7GlcNAc2 Man8GlcNAc2 
Iodomethane 
C70H128N2O36 C79H144N2O41 C88H160N2O46 C97H176N2O51 
[M+Na]+: 
1596.75 
[M+Na]+: 
1800.97 
[M+Na]+: 
2005.19 
[M+Na]+: 
2209.41 
Iodomethane-d3 
C70H56D72N2O36 C79H63D81N2O41 C88H70D90N2O46 C97H77D99N2O51 
[M+Na]+: 
1669.19 
[M+Na]+: 
1882.47 
[M+Na]+: 
2095.75 
[M+Na]+: 
2309.02 
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Table 3.5. Intra- and Interassay Reproducibility of Permethylation Procedures as 
Applied to Glycan Linkage Analysis of Blood Plasma. 
Glycan 
Nodes 
Average Intra-Assay CV%a Inter-Assay CV%a 
SCFb SC 10 minc SCFb SC 10 minc 
t-Fuc 5.3 6.6 17.8 12.3 
t-Gal 3.6 7.8 10.3 7.7 
2-Man 3.6 2.8 7.6 5.3 
4-Glc 45.2 13.5 54.7 15.6 
3-Gal 13.4 20.2 18.9 26.8 
6-Gal 3.8 2.7 10.8 9.8 
2,4-Man 7.6 6.4 13.2 11.2 
2,6-Man 5.2 5.8 8.9 6.5 
3,6-Man 8.9 13.2 16.5 15.7 
3,4,6-Man 4.6 7.4 18.7 19.0 
t-GlcNAc 3.2 5.0 6.6 4.9 
4-GlcNAc 2.0 2.1 6.5 2.9 
3-GalNAc 10.1 7.0 16.5 8.7 
3,4-GlcNAc 5.7 7.3 14.8 11.5 
4,6-GlcNAc 6.1 3.3 15.8 6.1 
3,6-GalNAc 9.9 12.2 18.2 15.4 
 
aValues represent %CV of total hexose or total HexNAc-normalized individual glycan 
nodes. All glycan nodes contributing at least 1% of the total hexose or HexNAc signal 
are listed.  
bData were acquired by one analyst on 7 separate days by the new spin column-free 
procedure.  
cData were acquired by 3 separate analysts on 3 separate days by the standard 10-minute 
spin column procedure74, 75. n = 6 samples per batch. 
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CHAPTER 4 
PREANALYTICAL HANDLING AND STORAGE VARIABILITY IN A 
MULTISITE-COLLECTION STUDY SIGNIFICANTLY IMPACTS ΔS-CYS-
ALBUMIN, A BLOOD PLASMA/SERUM INTEGRITY MARKER 
4.1 Introduction 
In the past two decades, significant advances have been made in bringing the 
issue of research biospecimen integrity to light177, 178. Recent studies have revealed 
that the pre-analytical variables (PAVs) pervading the collection, processing and 
storage of biospecimens may potentially generate samples with unknown or 
unrecognized integrity issues, thus leading to inaccurate and unreliable research 
results 88, 96, 179, 180. To address the issue of biospecimen integrity, efforts have been 
made toward the development of standard operating procedures (SOPs) for sample 
collection, processing and storage177, 181. However, the universal adoption of a single 
rigorous SOP, while in principle appealing as a solution to the development of 
potential biospecimen integrity problems, can, in practice, become impractical or 
impossible for laboratory personnel to implement on a rigorous basis for every sample 
or in situations where infrastructure issues arise such as unexpected power losses (see 
case study presented recently by Jeffs et al.102). This problem is amplified in studies 
with multiple collection sites involved—each of which must contend with different 
personnel and unique infrastructure constraints. Moreover, to date, many pre-clinical 
research studies have relied on pre-existing, archived biospecimens, some of which 
lack detailed paper trails documenting important PAVs. In 2014, a majority of the 455 
extramural grants sponsored by the U.S. National Cancer Institute (NCI, part of the 
National Institutes of Health) utilized pre-existing samples (63%); of these 455 grants, 
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107 of the projects (24%) relied on pre-existing blood plasma or serum samples92. 
Recently, using our recently developed ΔS-Cys-Alb marker, we discovered a major 
integrity discrepancy in a set of serum samples collected under NCI sponsorship and 
slated for distribution to other cancer researchers102. It would be naïve to assume that 
this was a single, isolated incident amongst all archived P/S samples slated for use in 
future research studies (or that may have already been used in published research 
studies). As such, there is a present and urgent need for accurate quality 
control/quality assurance (QC/QA) markers or tests to retrospectively assess the 
integrity of archived biospecimens—even those for which a nominally pristine paper 
trail may exist.  
Blood plasma/serum (P/S) samples, which can be routinely and quickly 
collected with minimal invasiveness, are among the most prevalently employed 
biospecimens in clinical research, particularly biomarker discovery research. In 2014, 
approximately 40% of NCI-sponsored grants involved the use of serum or plasma92. 
Several potential quality control markers for P/S integrity were outlined by Betsou et 
al178, including transferrin receptor182, potassium183, ACTH and BNP93, soluble 
CD40L184, vitamin C185, 186 and E187, MMP-7188, and etc. For nearly all of these 
candidate markers, the indication of disrupted sample integrity is grounded on the 
apparent loss of target analytes beyond their associated reference range.  
As previously reported102, 189, 190, human serum albumin contains a single free 
cysteine residue that can undergo spontaneous disulfide bond exchange with free 
cystine, forming S-cysteinylated albumin (S-Cys-Alb) to a limited degree in vivo and 
to a much greater extent when P/S samples are exposed to thawed conditions—i.e., 
temperatures > -30 °C 90, 91, 191, 192. Charge deconvoluted ESI‐mass spectra of albumin 
that illustrate the ex vivo formation of S-Cys-Alb are provided in Fig. 4.1. In the 
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presence of atmospheric oxygen and trace quantities of catalytic transition metals 
(primarily copper), nearly all of the cysteine equivalents in P/S (including those tied 
up as cystine) can be consumed by the native, reduced form of albumin producing S-
Cys-Alb 102. The number of cysteine equivalents in P/S is, on average, only about 
20% of the number of albumin equivalents126-128. As such, the fraction of albumin in 
the S-cysteinylated form within nearly all human P/S samples (which, in vivo, starts at 
~ 20-30%102, will increase by ~ 20% to 40-50% if P/S samples are exposed to thawed 
conditions for a long enough period of time (~ 60 days at -20 °C, ~ 25 days at 4 °C, ~ 
4-5 days at room temperature, and ~ 18 hrs at 37 °C102). 
Based on these facts, Jeffs et al recently developed an assay known as “ΔS‐
Cys‐Alb” as a QC/QA marker of P/S integrity102. This assay measures the S-Cys-Alb 
fraction change (ΔS‐Cys‐Alb) between the original P/S sample (presented with either 
a known or unknown storage history) and an aliquot of the same sample intentionally 
driven to its maximum ex vivo oxidation (S-cysteinylated) state. This inexpensive and 
rapid assay requires only 10 µL of a P/S sample and employs a very simple dilute-
and-shoot LC-MS based analysis. Since the associated rate law model for the 
formation of S-Cys-Alb at room temperature was also established102, back-calculation 
of the approximate time at which a given P/S samples must have been exposed to the 
equivalent of room temperature conditions was enabled—making it possible to place 
an “exposure time stamp” on every sample. 
As mentioned above, we applied the ΔS‐Cys‐Alb assay to a case study of 
nominally pristine serum samples collected under NCI-sponsorship and discovered a 
previously undisclosed biospecimen integrity discrepancy102. To evaluate the potential 
utility of this assay to reveal variations in biospecimen handling and storage 
conditions, we have now applied it to 413 clinical plasma samples from the Women 
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Epidemiology Lung Cancer (WELCA) study, that were collected under a single SOP 
but from 12 different collection sites and then sent to a single repository for long-term 
storage. Here we provide insights into the effects of initial P/S handling conditions on 
ΔS‐Cys‐Alb and evaluate the meaning of these results with regard to their 
implications for the stability of important clinical analytes within P/S samples 
collected in this manner. 
4.2 Materials and Methods 
4.2.1 Materials 
Trifluoroacetic acid (TFA, Cat. No. 299537) and formic acid (Cat. No. 06440) 
were obtained from Sigma-Aldrich (St. Louis, MO). Acetone (Cat. No. L-16923) and 
HPLC grade water (Cat. No. L16978) were acquired from ThermoFisher Scientific 
(Waltham, MA).  
4.2.2 Samples 
EDTA plasma samples from stage I-IV lung cancer patients and age-matched 
controls of Women Epidemiology Lung Cancer (WELCA) study were collected at 12 
different collection centers in France under the supervision of Dr. Isabelle Stücker. This 
study was approved by Institutional Review Board of the French National Institute of 
Health and Medical Research and by the French data Protection Authority (IRB-Inserm, 
no. 3888 and CNIL no. C13-52). As part of the Women Epidemiology Lung Cancer 
Study, all-female lung cancer patients were recruited between September 2014 and 
November 2016 in collection sites 2 to 14, and age-matched all-female controls were 
recruited between June 2015 and December 2016 in collection site 18. All women 
living in Paris and the lle de France area, newly diagnosed with lung cancer were 
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considered as eligible cases. Age matched controls were randomly sampled from 
women without a history of cancer living in the same area. All Peripheral blood samples 
were drawn and processed following a written standardized protocol150. Briefly, after 
transported to the laboratory at 4 °C, blood samples collected in tubes containing EDTA 
additive were spun for 15 min at 3000 rpm and 4 °C in a standard centrifuge. In each 
of the 12 collection centers, the collected plasma samples were aliquoted and 
periodically (almost every three months) transported in dry ice to the central repository 
for final storage at -80 °C. No freeze-thaw cycles occurred prior to shipment to Arizona 
State University (Borges lab) for analysis. Received plasma samples were aliquoted on 
ice and kept frozen at -80 ℃ prior to any analysis. 
Sample handling information including collection site, pre-centrifugation delay 
(from blood drawing to centrifugation), post-centrifugation delay (from centrifugation 
to storage), total pre-storage delay time (from blood drawing to storage), and initial 
storage temperature prior to shipment to the central repository were gathered and 
tabulated from the 413 corresponding sample collection information sheets.  
A 300-mL plasma sample from an individual donor was obtained from BioIVT, 
which served as a quality control sample to ensure batch-to-batch quantitative 
reproducibility.  
4.2.3 Experimental procedures 
Sample preparation: Plasma samples, run in random order, were simply diluted 
1000-fold before injection onto an LC-MS. Generally, a 10 μL aliquot of plasma was 
thawed at room temperature. Once completely in liquid status, 0.5 μL of plasma was 
added to 500 μL of 0.1 % (v/v) TFA and mixed thoroughly by vortexing for 20 s. Then 
the freshly diluted plasma solution was injected onto the LC-MS instrument 
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immediately. To intentionally drive the degree of albumin S-cysteinylation to its 
maximum value, the residual 9.5 μL plasma sample was incubated at 37 ℃ for 18 hrs 
in a 600-μL Eppendorf snap-cap test tube. Afterward, 0.5 μL of the sample (in fully 
oxidized state) was diluted 1000-fold and then loaded onto LC-MS, following the same 
steps described above.   
LC-ESI-MS Analysis: The separation and relative quantification of intact 
albumin proteoforms were performed on an Agilent 1260 Infinity II UHPLC connected 
to an Agilent 6530 Electrospray Ionization Quadrupole Time-of-Flight (Q-TOF) LC-
ESI-MS instruement. A 10 μL of sample was loaded at 200 μL/min in 80% water 
containing 0.1% formic acid (Solvent A) / 20% acetonitrile containing 0.1% formic 
acid (Solvent B) onto an Optimize Technologies protein captrap configured for bi-
directional flow on a 6 – port diverter valve. The same solvent composition was held 
for 1 minute at 200 μL/min to rinse the protein captrap. Following were stepwise ramps 
of the flow composition to elute the trapped albumin at 200 μL/min: 3.0 – 3.1 min, 
ramped to 65/35 A/B and held until 4.5 min; 4.5 – 4.6 min, ramped to 55/45 A/B then 
held until 7.5 min; 7.5 – 7.6 min, ramped to 20/80 A/B and held until 8.6 min; at last, 
ramped back to 80/20 A/B by 8.7 min. This stepwise gradient results in near complete 
chromatographic separation of albumin from apolipoprotein A-I. A 4-minute post-run 
program was implemented at 200 μL/min of 80/20 A/B to reconstitute the system with 
the solvent composition of sample loading. The 6 – port valve was initially set to the 
loading position (1-2) and then switched to the inject position (1-6) at 3 minutes, 
directing the eluate from the captrap to the mass spectrometer. The mass spectrometer 
was set to run in positive ion, TOF-only mode and to collect spectra in m/z 100 to 3200 
range. ESI settings for the Dual AJS ESI capillary microflow nebulizer ion source were 
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as follows: VCap 5700 V, Capillary 8.193 μA, Nozzle Voltage (Expt) 2000 V, Chamber 
25.87 μA, Drying Gas nitrogen 7 L/min at 325 ℃, Nebulizer nitrogen 45 psig, Sheath 
Gas 11 L/min at 250 ℃. Data were acquired in profile mode at a rate of 1 spectra/s.  
4.2.4 Data Processing 
Across the chromatographic peak apex of albumin (retention time 5.5-5.9 min), 
approximately 0.3 minute of recorded spectra were averaged. Then deconvolution by 
the MaxEnt algorithm was carried out on the electrospray ionization charge-state 
envelope with Agilent MassHunter Qualitative Analysis vB.07.00 software. The 
MaxEnt algorithm parameters were set as follows: mass range 60000.00 – 72000.00 
daltons, mass step 1.0000 daltons, using limited m/z range 1000 – 2500 m/z, subtracting 
baseline with baseline factor 0.7, adduct as proton, peak height filter with peak signal-
to-noise ratio >= 10.0, maximum number of peaks limited (by height) to the largest 100, 
calculating average mass using top 90% of peak height, minimum consecutive charge 
states 10, and minimum protein fit score 8. In the deconvoluted spectra, the peak heights 
of mass spectral peaks of interest were exported to a spreadsheet for further statistical 
analysis.  
The fractional abundance of S-cysteinylated albumin (oxidized form, S-Cys-
Alb) was calculated by dividing the height of the peak representing S-Cys-Alb by the 
sum of the peak heights for native albumin and S-Cys-Alb. The change of S-Cys-Alb 
fraction (ΔS-Cys-Alb) for each plasma sample was determined by subtracting the S-
Cys-Alb of the sample in its original state from the S-Cys-Alb of the same sample in 
its fully oxidized state.  
Statistical analysis was performed in GraphPad Prism 7: For the four groups 
with different initial handling conditions, outliers were removed by log-transformation 
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and the ROUT method at Q = 1%. Outlier-removed data were then reverse-transformed 
by taking the anti-log of each value. To identify differences among groups, the Kruskal-
Wallis test at 95% confidence level followed by the Benjamini-Hochberg false 
discovery correction procedure at a 5% false discovery rate was carried out. Correlation 
of ΔS-Cys-Alb with various delays were evaluated by spearman’s rank correlation in 
GraphPad Prism 7. Differences between lung cancer patients and controls were 
assessed by means of the Mann-Whitney test at a 95% confidence level. GraphPad 
Prism 7 was also used to plot all the figures.  
4.3 Results 
For all 413 blood plasma samples obtained from the WELCA study, ΔS-Cys-
Alb was measured in 33 batches. Samples were analyzed in random order. A quality 
control (QC) EDTA plasma sample was aliquoted and measured in each batch and 
indicated reasonable total interassay precision (%CV = 12.4%; at an S-Cys-Alb value 
of 20%, this corresponds to an S-Cys-Alb variability of 2.5%). 42 
4.3.1 Effect of Initial Handling Conditions on ΔS-Cys-Alb 
The effects of initial storage temperature (prior to shipment to the central 
repository) and total pre-storage delay on ΔS-Cys-Alb were evaluated first. Post 
analysis, blood plasma samples were divided into four groups based on their initial 
handling conditions: 1) samples stored at -80 ℃ within 3 hours from blood drawing; 2) 
samples stored at -80 ℃ but exposed to 4 ℃ or higher temperature for  longer than 3 
but less than 16 hours before storage at -80 ℃ , and 3) samples stored at -80 ℃ but 
exposed to 4 ℃ or higher temperature for longer than 16 hours before storage at -80 ℃ , 
and 4) samples stored at -20 ℃ for 42 up to 456 days. As might be expected based on 
the known stability of ΔS-Cys-Alb102, pronounced, statistically significant differences 
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were observed in each group compared to one another (Fig. 4.2). Since ΔS-Cys-Alb 
measures the difference in the S-Cys-Alb fraction between the original status and fully 
oxidized status of a sample, a smaller ΔS-Cys-Alb represents more ex vivo oxidation 
had occurred in the sample prior to any analysis. The ΔS-Cys-Alb values of samples 
stored temporarily at -20 ℃ were found to be significantly lower than those stored in -
80 ℃, indicating a definitively higher ex vivo oxidation level of albumin and 
compromised sample integrity. Moreover, for all the samples stored initially at -80 ℃, 
longer pre-storage delay at 4 ℃ also led to strikingly decreased ΔS-Cys-Alb value, 
implying possibly jeopardized sample integrity.   
Next, because detailed information on pre- and post-centrifugation delay in 
hours as well as total pre-storage delay were available for most samples, the correlation 
of ΔS-Cys-Alb to each of these delay time categories was assessed. Spearman’s rank 
correlation analysis demonstrated that ΔS-Cys-Alb was significantly correlated with 
pre-centrifugation delay (Fig. 4.3a) and total pre-storage delay (Fig. 4.3c), both with a 
moderate negative relationship (r = -0.522 and -0.524, respectively). When focusing on 
correlation to post-centrifugation delay, samples with pre-centrifugation delay longer 
than 3 hours were excluded to circumvent this potentially confounding factor. Thus, no 
statistically significant correlation was discovered between ΔS-Cys-Alb and post-
centrifugation delay (Fig. 4.3b)—probably due to the relatively short delay time (< 2 
hrs) after centrifugation for these samples. Together, these data revealed that delay time 
prior to samples being stored at less than -30 ℃, primarily before centrifugation, can 
adversely affect the ΔS-Cys-Alb values of plasma samples.  
As reported in our previous work102, the theoretical reference range of ΔS-Cys-
Alb in P/S for 99% of the population has been predicted as 11 – 39% (yellow shaded 
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area in Fig. 4.2), which was calculated from the already known human population 
average plasma concentrations of albumin, cystine and cysteine126-128. In total, 96.7% 
of the ideally handled plasma samples from WELCA study, those stored in -80 ℃ 
within 3 hours from blood drawing, exhibited ΔS-Cys-Alb between 11 – 39%, 
indicating that this predicted theoretical range is almost certainly valid with regard to 
its application to lung cancer patient plasma samples.  
4.3.2 ΔS-Cys-Alb at different collection sites 
The distribution of ΔS-Cys-Alb observed at different collection sites is depicted 
in Fig. 4.4. As described above, plasma samples of lung cancer patients were collected 
at sites 2 to 14, and that of controls were obtained only at site 18. Among all 12 sample 
collection sites, sites 5 and 11 were obviously distinguished from the other sites, with 
markedly lower ΔS-Cys-Alb values (Fig. 4.4a). These findings were aligned with the 
fact that plasma samples collected from site 11 were all temporarily stored in -20 ℃ 
before being sent to the central repository (from 43 to 271 days), while in site 5 all 
samples except one (with ΔS-Cys-Alb value as 0.163) were stored temporarily at -20 ℃ 
(for 42 to 456 days). ΔS-Cys-Alb values from site 18 were also distinctive—exhibiting 
a lower and more widely spread range of ΔS-Cys-Alb values (Fig. 4.4a). At each 
collection site, collected and initially processed plasma samples were periodically 
(almost every three months) transported to the central repository biobank for final 
storage at -80 °C. Yet, since the plasma samples of the 208 lung cancer patients were 
collected from 11 dispersed sites, less than three batches each of lung cancer samples 
were acquired from sites 2 to 14. However, for site 18, a total of eight batches of plasma 
samples were gathered and sent to the central repository, two of which (received by the 
central repository in September and October 2016, respectively) demonstrated 
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statistically significant lower range of ΔS-Cys-Alb (Fig. 4.4b).  
4.3.3 Equivalent time exposed to room temperature 
Using the rate law-based mathematical model of S-Cys-Alb formation in P/S ex 
vivo established by our research group102, the approximate time that an average P/S 
specimen has been exposed to room temperature (23 ℃) can be back-calculated from 
a measured ΔS-Cys-Alb value. Referring to the table provided by Jeffs et al 102 where 
the rate law model-predicted P/S ΔS-Cys-Alb values were listed for 1 to 8 days exposed 
to 23 ℃, the equivalent time of exposure to room temperature of each WELCA plasma 
sample was determined and depicted in Fig. 4.5. Samples were color-coded by 
collection site. Most samples from site 5, 11 and some from site 18 stood out from the 
rest, particularly in the range where the equivalent time exposed to room temperature 
was longer than 1 day. Taken along with the site-specific sample handling conditions 
described above, these data reveal that samples stored at -20 ℃ (for 42 to 456 days) 
exhibited the lowest ΔS-Cys-Alb values and therefore the greatest exposure time to the 
equivalence of 23 °C (as far as this particular marker is concerned).  
4.3.4 Comparison of ΔS-Cys-Alb between lung cancer patients and controls 
The oxidized form of P/S albumin has been proposed and employed as a marker 
for conditions related to oxidative stress193-196, including chronic liver and kidney 
diseases and diabetes mellitus109. Given the data provided here and in our previous 
publications describing the ex vivo oxidation (S-cysteinylation) of albumin, it is clear 
that neither S-Cys-Alb or ΔS-Cys-Alb should be put forth as biomarkers of disease in 
the absence of extremely rigorous control and documentation of preanalytical handling 
and storage conditions. Nevertheless, in a study like this one, we would be remiss to 
not compare S-Cys-Alb and ΔS-Cys-Alb in the control samples to that of the cancer 
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patient samples (Fig. 4.6). Statistically significant differences were detected for both S-
Cys-Alb and ΔS-Cys-Alb, but the distributions of the cancer patient population 
contained the entire control group population within itself and the mean ± SD values of 
the two patient groups were quite close (S-Cys-Alb: lung cancer cases, 0.296 ± 0.107; 
controls, 0.316 ± 0.072; ΔS-Cys-Alb: lung cancer cases, 0.156 ± 0.079; controls, 0.136 
± 0.056). 
4.4 Discussion 
The results presented above suggest that ΔS-Cys-Alb is quite sensitive to most 
initial biospecimen handling and storage conditions involving plasma sample 
exposure to thawed conditions (> -30 ℃). They also confirm that ΔS-Cys-Alb is non-
linearly and inversely correlated with the time delay prior to storage—including and 
perhaps especially before centrifugation. A vast majority of properly handled samples 
(stored in -80 ℃ within 3 hours from blood drawing) fell within the previously 
reported theoretical population reference range (11 – 39%) of ΔS-Cys-Alb. Recent 
findings by Jeffs et al.102 in fresh P/S collected from non-acute cardiovascular patients 
have also empirically confirmed this range, with the measured ΔS-Cys-Alb values in 
95% of fresh cardiac patient plasma fall in the range of 14 – 30%. (Further validation 
in fully healthy donors is presently underway.) 
The thawed state exposure times documented on paper and evidenced by the 
ΔS-Cys-Alb assay in this study were categorized into four initial handling/storage 
conditions (as illustrated in Fig. 4.2a). Other investigators have reported clinical 
analytes that were unstable under each of these four conditions, as listed in Table 4.1. 
A total of 6, 18, 64 and 54 commonly measured clinical analytes were found to be 
unstable under the four categories of handling/storage conditions, respectively. The 
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range of unstable clinical analytes included metabolites (vitamins, fatty acid, etc.), 
peptides and proteins (Lipoproteins, Prostate Specific Antigens, etc.), hormones 
(Insulin, Leptin, etc.), cell-free DNA, and inorganic cations/anions (Potassium, 
Bicarbonate, etc.) (Table 4.1). 
When viewed in line with the findings documented in Table 4.1, the results 
from this study showed that temporary storage of plasma at -20 ℃ at satellite 
collection sites has a major impact on the integrity of samples treated in this manner. 
Although P/S samples appear to be frozen at -20 ℃, they are only actually frozen 
when the temperature is below -30 ℃90, 91. Moreover, temporary storage at 4 ℃ for 
more than 3 hours is generally ill-advised, because many more analytes start to lose 
stability with delay times longer than 3 hours (Table 4.1).  
In light of the observations from this study, the ΔS-Cys-Alb assay may serve 
as a valuable tool to assess P/S integrity—especially for P/S samples for which 
handling and storage paper trails do not exist or may be of poor quality. Furthermore, 
pristine paper trails are sometimes insufficient to guarantee that sample integrity is not 
compromised by incidents. As reported by Jeffs et al., in a set of serum samples for a 
stage I lung cancer study, collected under NIH-sponsorship by seasoned investigators 
with a well‐defined SOP, an explicit integrity discrepancy between cases and controls 
was detected by the ΔS-Cys-Alb assay 102. After discovery, the integrity discrepancy 
was ultimately disclosed in detail by the clinical investigators who had provided the 
samples. In short, the ‐80 °C freezers in which the control samples had been stored 
had experienced a power outage for about 3‐4 days during a natural disaster. As 
shown in Fig. 4.4b, substantial integrity discrepancies were observed between batches 
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of samples from the same site in this study (site 18). The explanation for this fact has 
not yet come to light—but it has, at least, been documented empirically. 
ΔS-Cys-Alb is a novel marker for P/S integrity.  Because it requires LC/MS, 
many laboratories will not be equipped to run it. However, the easy dilute-and-shoot 
nature of the ΔS-Cys-Alb assay along with its lack of requirement for a high-end LC-
MS instrument means that nearly every MS facility and every major clinical reference 
lab is readily capable of running it. Moreover, investigators should bear in mind that 
to make a credible evaluation on sample sets, it is not always necessary to analyze 
every single sample; rather spot-checking a subset of each sample set that has been 
handled/stored together will, in many cases, suffice to empirically document P/S 
specimen integrity.  
4.5 Conclusion 
A simple dilute-and-shoot, intact-protein LC-MS assay known as ΔS-Cys-Alb 
that quantifies cumulative exposure of P/S samples to their thawed conditions (> -30 °C) 
was employed to evaluate the effect of various initial handling and storage conditions 
on P/S integrity in a clinical study involving multisite sample collection. ΔS-Cys-Alb 
values were dramatically lowered under conditions of prolonged pre-processing/pre-
storage delay times at 4 °C and at an elevated temporary storage temperature (-20 °C) 
prior to shipment to the central repository where samples were permanently stored at -
80 °C. In accord with a previously established rate law for the ex vivo formation of S-
Cys-Alb in P/S, ΔS-Cys-Alb values were found to be non-linearly correlated with delay 
time prior to centrifugation as well as prior to storage. In consideration of the important 
clinical analytes that were unstable under the four categories of initial handling/storage 
conditions, ΔS-Cys-Alb will likely find utility as a tool to access P/S integrity. 
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Figures 
 
Figure 4.1. Charge deconvoluted ESI‐mass spectra of albumin that illustrate ΔS‐Cys‐
Alb. The black spectrum is from a fresh sample obtained immediately after 
centrifugation. The red spectrum is from the same sample stored for 60 days at ‐20 °C. 
As indicated, small fractions of albumin are N‐terminally truncated, and both the native 
and S‐cysteinylated forms may be glycated. This figure was originally published in 
Molecular & Cellular Proteomics122. © the American Society for Biochemistry and 
Molecular Biology. 
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Figure 4.2. Effect of storage temperature and pre-storage delay on ΔS-Cys-Alb. (a) 
Univariate distribution of ΔS-Cys-Alb from four sample groups with different initial 
handling conditions. “-80 °C, <3h” represents the initial handling condition as 
samples were stored at -80 ℃ within 3 hours from blood drawing. Similarly, “-80 °C, 
3-16h” and “-80 °C, >16h” stand for conditions under which samples were delayed 
before storage at -80 ℃ for 3 to 16 hours, and longer than 16 hours, respectively. 
Samples in the “-20 °C” group were initially stored at -20 ℃ for 42 up to 456 days 
prior to shipment to the central repository. Error bars represent mean ± SD, n = 124, 
162, 70 and 46 for the four groups respectively. Eleven samples were excluded from 
the total 413 samples due to lack of initial handling information. The yellow shaded 
area indicates the theoretical reference range of ΔS-Cys-Alb in P/S (11 – 39%). The 
Kruskal−Wallis test was performed followed by the Benjamini−Hochberg false 
discovery correction procedure. The different letters above the data points in panel a) 
indicate statistically significant differences between groups (p < 0.0001 for each 
between-group comparison). (b) ROC curves for the three groups compared to the 
group with ideally handled samples (-80C, <3h). Areas under the ROC curves are 
provided in parenthesis next to the specified stages. For all three ROC curves, p < 
0.0001. 
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Figure 4.3. Correlation between pre- (a) and post-centrifugation delay (b), total pre-
storage delay (c) and ΔS-Cys-Alb. Spearman’s rank correlation coefficients are 
provided above the data points. “****” next to the coefficients in (a) and (c) indicates 
that the Spearman’s rank correlation was statistically significant with p < 0.0001. 
“NS” next to the coefficient in panel b indicates a statistically insignificant 
Spearman’s rank correlation. 
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Figure 4.4. Univariate distribution of ΔS-Cys-Alb (a) at the different WELCA study 
collection sites, and (b) from different collection batches at site 18. The 
Kruskal−Wallis test was performed followed by the Benjamini−Hochberg false 
discovery correction procedure. The letters at the top of each set of data points within 
each panel demonstrate statistically significant differences between groups (p < 0.05); 
any overlap in letters indicates a lack of significant differences between groups (p ≥ 
0.05). 
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Figure 4.5. Estimate of plasma sample exposure times to the equivalent of 23 °C 
based on the rate law for formation of S-Cys-Alb102. Plasma samples collected at 
different sites were color-coded as illustrated in the legend on the right side. The 
curved line traced out by the data points represents the rate law-predicted ΔS-Cys-Alb 
value in a plasma sample with population-wide average initial concentrations of 
albumin, cystine, cysteine and copper 102. The upper curved dashed line was 
calculated based on starting albumin and total copper concentrations of two SDs 
below the population mean but with a cystine concentration two SDs above the 
population mean; the lower curved dashed line was similarly calculated based on 
starting albumin and total copper concentrations of two SDs above the population 
mean but with a cystine concentration two SDs below the population mean. Thus, for 
each data point, the horizontal range between the two dashed black dashed lines 
represents the population-wide possible error for the calculated time of exposure to 
the equivalence of room temperature. Even though ΔS-Cys-Alb should, theoretically, 
always be positive, some slightly negative ΔS-Cys-Alb values were observed due to a 
modest degree of analytical error. 
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Figure 4.6. Univariate distribution of (a) S-Cys-Alb and (b) ΔS-Cys-Alb for lung 
cancer patients and controls. Mann-Whitney test was performed for both comparisons, 
with the letters above data points indicating statistically significant difference (p < 
0.0001) between case and control groups. n = 207 for controls and n = 206 for lung 
cancer patients. 
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Tables 
Table 4.1. Compilation of Studies Describing the Stabilities of Clinical Analytes in 
Blood Specimens under Various Initial Handling/Storage Conditionsa. 
Initial 
handling/s
torage 
conditions 
Biospecime
n Stable Analytes Unstable Analytes Reference 
4 ° C for < 
3 h  
Serum  folic acid 197 
Plasma ascorbic acid  185 
Serum  free prostate specific antigen (PSA) 198 
Serum  cell-free DNA 199 
Serum  ACTH 93 
Whole blood  potassium, glucose 200 
4 ° C for 3-
16 h  
Serum 13 fatty acids  197 
Plasma cell-free DNA  199 
Serum  free PSA 201 
Serum  transferrin receptor 182 
Plasma/Serum  ascorbic acid 185 
Whole blood  
inorganic phosphorous, 
bicarbonate, lactate 
dehydrogenase, magnesium, 
activated partial thromboplastin 
time (APTT), C-telopeptide, 
adrenocorticotrophic hormone 
(ACTH) 
200 
Plasma/Serum  
potassium, bicarbonate, lactate, 
glucose, magnesium, APTT, 
osteocalcin, C-telopeptide 
4 ° C for > 
16 h  
Serum C-reactive protein, retinol, ferritin fatty acids (13) 197 
P/S 
aldosterone, α-subunit 
total, α-subunit free, AVP, 
CRH, C-peptide, FSH, 
glucagon, GH, IGF-1, 
IGF-BP3, insulin, leptin, 
LH, PPP, PTH, prolactin, 
VIP 
 93 
Plasma  ACTH 
Plasma vitamin B12 folate 202 
Serum total PSA  201 
Serum total PSA, complex PSA  198 
Serum apolipoprotein E  101 
Serum 
cholesterol (IDL), 
triglycerides (VLDL, 
IDL), phospholipids 
(VLDL, IDL, LDL), 
proteins (VLDL, IDL, 
LDL, HDL) 
VLDL cholesterol, LDL 
cholesterol, LDL triglycerides, 
HDL cholesterol, HDL 
triglycerides, HDL 
phospholipids 
203 
Serum 
palmitic acid, palmitoleic 
acid, stearic acid, oleic 
acid, linoleic acid, γ-
linolenic acid, α-linolenic 
acid, dihomo-γ-linolenic 
acid, arachidonic acid, 
eicosapentaenoic acid, 
docosapentaenoic acid, 
docosahexaenoic acid, 
saturated fatty acid, mono 
myristic acid 204 
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unsaturated fatty acid, ω 
3-polyunsaturated fatty 
acid, ω 6-polyunsaturated 
fatty acid 
Plasma/Serum C-telopeptides of type I collagen (CTX)  205 
Plasma  Cell-free DNA 199 
Plasma  catecholamines 206 
Whole blood  potassium 183 
Whole blood  
lactate, mean corpuscular 
volume, mean corpuscular 
hemoglobin, follicle-stimulating 
hormone (FSH), estradiol, 
prolactin, folate, insulin, C-
peptide, parathyroid hormone 
(PTH), osteocalcin 
200 
Plasma/Serum  
inorganic phosphorous, lactate 
dehydrogenase, FSH, estradiol, 
prolactin, folate, insulin, C-
peptide, PTH 
Plasma  
sphingosine (d18:1), 
sphingadienine (d18:2), 
sphingosine (d16:1), glycerate, 
5-hydroxyeicosatetraenoic acid 
(C20:trans[6]cis[8,11,14]4) (5-
HETE), threonic acid, 3,4-
dihydroxyphenylacetic acid 
(DOPAC), 3,4-
dihydroxyphenylglycol 
(DOPEG)), Pentraxin-3, 10 
peptides identified from 
fibrinogen, complement C4B 
and complement C3 
207 
-20˚C for 2 
m to 5 y 
Plasma vitamin B6, vitamin B12, folic Acid, vitamin D 
vitamin A, carotenoids, vitamin 
E 187 
Whole blood vitamin B1, vitamin, niacin  
Serum anti-dengue IgM, anti-dengue IgG  208 
Serum 
C-reactive protein, 
creatine kinase, lactate 
dehydrogenase, AST, 
GGT, lipase, albumin, 
transferrin 
amylase, alanine-amino 
transferase, alkaline phosphatase 209 
Serum MMP-7 TIMP-1, VEGF, VEGF-receptor (Unstable after 3 m) 98 
Serum total PSA free PSA 201 
Serum 
LDL cholesterol, LDL 
phospholipids, LDL 
proteins 
ApoB, cholesterol (VLDL, IDL, 
HDL), triglycerides (VLDL, 
IDL, LDL, HDL), phospholipids 
(VLDL, IDL, HDL), proteins 
(VLDL, IDL, HDL) 
203 
Serum 
palmitic acid, palmitoleic 
acid, r-Linolenic acid, 
arachidonic acid, 
eicosapentaenoic acid, 
docosahexaenoic acid, 
saturated fatty acid, mono 
unsaturated fatty acid, ω 
3-polyunsaturated fatty 
acid 
myristic acid, stearic acid, oleic 
acid, linoleic acid, α-linolenic 
acid, dihomo-γ-Linolenic acid, 
Docosapentaenoic acid, ω 6-
Polyunsaturated fatty acid 
204 
Plasma/Serum C-telopeptides of type I collagen (CTX)  205 
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Serum  folate 210 
Plasma  catecholamines (Unstable after 1 m) 206 
Serum  free PSA 198 
Plasma/Serum  ascorbic acid (Unstable after 3 m) 185 
Serum  apolipoprotein E (Unstable after 3 m) 101 
Plasma  
thromboplastin, prothrombin, 
thrombin, fibrinogen, 
coagulation factors II, V, VII, 
VIII, IX, X, XI and XII, protein 
C, protein S, antithrombin, 
plasminogen, von Willebrand 
factor, D-dimer (Unstable after 3 
m) 
99 
     
a“h” stands for hour; “m” represents month; “y” represents year. 
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CHAPTER 5 
CONCLUSION AND FUTURE DIRECTIONS 
In this dissertation, the diagnostic and prognostic capacity of plasma glycan 
features in stage I-IV lung cancer—as represented by monosaccharide and linkage-
specific glycan nodes—were validated in the WELCA case-control study. Significant 
elevation of α2‐6 sialylation, β1‐4 branching, β1‐6 branching, outer‐arm fucosylation 
and total N-glycosylation level, were observed in almost every stage of lung cancer 
relative to age-matched control groups. Alteration of glycan features in lung cancer was 
independent of smoking status, age and histological subtypes of lung cancer. 
Furthermore, the above six glycan features predicted all-cause mortality in lung cancer 
patients after adjusting for age, smoking status, and cancer stage. Early-stage detection 
was stronger than that previously observed by the Borges group, but this observation 
may have been related to the lack of smoking status-matching between cases and 
controls in the WELCA study. No gender-based differences were discovered in glycan 
features associated with lung cancer. 
According to related studies previously reported by Borges group, some of the 
altered glycan features were also observed from a variety of other cancer types, such as 
pancreatic, ovarian, prostate, bladder and breast cancers, indicating that the alteration 
of many glycan features is arisen from inflammatory processes common to a majority 
of cancers. Further studies are needed to elucidate the mechanism of how the cancerous 
processes modulate changes in blood glycan biochemistry, as well as to shed light on 
the essential roles of these prevalent glycan features in the metastasis and progression 
of cancer. 
To simplify the sample preparation steps and reduce consumable costs for 
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glycan permethylation, the first and most crucial step of glycan node analysis, a spin 
column-free (SCF) permethylation procedure was developed and applied to mass 
spectrometry-based glycan node analysis and intact-glycan analysis, with comparable 
or slightly better permethylation yields for N- and O-linked glycans as well as hexose 
and HexNAc residues. Furthermore, the new SCF procedure was approved to facilitate 
glycan node analysis of pooled glycans from unfractionated blood plasma with good 
quantitative reproducibility and dianostic capacity for late stage breast cancer. In the 
future, the performance of this new SCF procedure should be validated by applying it 
to cancer sets with larger sample size. 
Although blood plasma glycans were discovered to be quite stable under a 
variety of sample storage conditions, the less-than-ideal conditions that expose P/S 
samples to their thawed conditions (> -30 °C) could have detrimental effects on a 
variety of clinical analytes. A simple dilute-and-shoot, intact-protein LC-MS assay 
known as ΔS-Cys-Alb was employed to evaluate the effect of various initial handling 
and storage conditions on P/S integrity in a clinical study involving multisite sample 
collection. It was revealed that prolonged pre-processing/pre-storage delay times at 
4 °C and at an elevated temporary storage temperature (-20 °C) prior to the permanent 
storage at -80 °C could dramatically lower ΔS-Cys-Alb values. In line with a previously 
established rate law for the ex vivo formation of S-Cys-Alb in P/S, ΔS-Cys-Alb values 
were found to be non-linearly correlated with delay time prior to centrifugation as well 
as prior to storage. It is also pivotal to know that ΔS-Cys-Alb decays in a time frame 
that aligns well of plenty of other clinically important analytes present in P/S 
biospecimens. Therefore, ΔS-Cys-Alb will likely find utility as a robust, 
mechanistically understood tool to access P/S integrity and thus reduce the number of 
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misleading discoveries in biomarker research. 
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